diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12507diaendo-12507Research ArticleКлинические рекомендацииClinical GuidelinesСахарный диабет 2 типа у взрослыхDiabetes mellitus type 2 in adultshttps://orcid.org/0000-0002-8175-7886ДедовИван ИвановичDedovIvan I.

д.м.н., профессор, академик РАН

MD, PhD, Professor

dedov@endocrincentr.ruhttps://orcid.org/0000-0003-3893-9972ШестаковаМарина ВладимировнаShestakovaMarina V.

д.м.н., профессор, академик РАН

MD, PhD, Professor

nephro@endocrincentr.ruhttps://orcid.org/0000-0001-9453-8212МайоровАлександр ЮрьевичMayorovAlexander Y.

д.м.н.

MD, PhD

education@endocrincentr.ruhttps://orcid.org/0000-0002-3433-0142ШамхаловаМинара ШамхаловнаShamkhalovaMinara S.

д.м.н.

MD, PhD

shamkhalova@mail.ruhttps://orcid.org/0000-0002-3443-7206СухареваОльга ЮрьевнаSukharevaOlga Yu.

кандидат медицинских наук, ведущий научный сотрудник, отделение диабетической болезни почек и пострансплантационной реабилитации, Институт диабет

PhD

olgasukhareva@mail.ruhttps://orcid.org/0000-0001-6581-4521ГалстянГагик РадиковичGalstyanGagik R.

д.м.н., профессор

MD, PhD, Professor

galstyangagik964@gmail.comhttps://orcid.org/0000-0003-2474-9924ТокмаковаАлла ЮрьевнаTokmakovaAlla Y.

д.м.н.

MD, PhD

alla-tokmakova@yandex.ruhttps://orcid.org/0000-0001-5656-2596НиконоваТатьяна ВасильевнаNikonovaTatiana V.

д.м.н., профессор

MD, PhD, Professor

tatiana_nikonova@mail.ruhttps://orcid.org/0000-0002-3973-7638СурковаЕлена ВикторовнаSurkovaElena V.

д.м.н.

MD, PhD

elena_surkova@mail.ruhttps://orcid.org/0000-0003-4929-1526КононенкоИрина ВладимировнаKononenkoIrina V.

к.м.н., старший научный сотрудник отделения наследственных эндокринопатий Института персонализированной медицины ФГБУ «НМИЦ эндокринологии» Минздрава России

PhD

shakhtarina@bk.ruhttps://orcid.org/0000-0002-5031-7183ЕгороваДарья НикитичнаEgorovaDaria N.

к.м.н., с.н.с. отделения диабетической стопы

MD, PhD, senior research associate

egoorovadasha@yandex.ruhttps://orcid.org/0000-0003-3535-520XИбрагимоваЛюдмила ИбрагимовнаIbragimovaLyudmila I.

к.м.н.

MD, PhD

ibragimovaliudmila@gmail.comhttps://orcid.org/0000-0001-6612-6851ШестаковаЕкатерина АлексеевнаShestakovaEkaterina A.

кандидат медицинских наук, ведущий научный сотрудник консультативно-диагностического отделения

MD, PhD

katiashestakova@mail.ruКлефортоваИнна ИгоревнаKlefortovaInna I.

к.м.н., ведущий научный сотрудник отделения диабетической болезни почек и посттрансплантационной реабилитации

Ph.D., Leading Researcher, Department of Diabetic Kidney Disease and Post-Transplant Rehabilitation

iklefort@mail.ruhttps://orcid.org/0000-0002-7768-4717СкляникИгорь АлександровичSklyanikIgor A.

аспирант

MD, PhD student

sklyanik.igor@gmail.comЯрек-МартыноваИвона ЯновнаYarek-MartynovaIvona Ya.

к.м.н., заместитель директора Института диабета по лечебной работе, ведущий научный сотрудник отделения диабетической болезни почек и посттрансплантационной реабилитации

Candidate of Medical Sciences, Deputy Director of the Institute of Diabetes for Medical Work, Leading Researcher at the Department of Diabetic Kidney Disease and Post-Transplant Rehabilitation

iwonamj@mail.ruhttps://orcid.org/0000-0002-0296-4933СеверинаАнастасия СергеевнаSeverinaAnastasia S.

к.м.н., ведущий научный сотрудник

MD, PhD

ansev1@mail.ruhttps://orcid.org/0000-0003-2257-3224МартыновСергей АндреевичMartynovSergey A.

кандидат медицинских наук, ведущий научный сотрудник, отделение диабетической болезни почек и пострансплантационной реабилитации, Институт диабет

PhD

smartynov@inbox.ruhttps://orcid.org/0000-0003-0571-8882ВикуловаОльга КонстантиновнаVikulovaOlga K.

к.м.н., доцент

MD, PhD, associate professor

gos.registr@endocrincentr.ruhttps://orcid.org/0000-0001-5573-0754КалашниковВиктор ЮрьевичKalashnikovViktor Y.

д.м.н., профессор, член-корреспондент РАН

MD, PhD, Professor

victor9368@gmail.comhttps://orcid.org/0000-0002-5178-6029БондаренкоИрина ЗиятовнаBondarenkoIrina Z.

д.м.н., гл.н.с.

MD, PhD, chief research associate

iz_bondarenko@mail.ruhttps://orcid.org/0000-0001-6318-1345ГомоваИрина СергеевнаGomovaIrina S.

к.м.н., врач отдела кардиологии и сосудистой хирургии Института диабета 

Candidate of Medical Science, Physician of the Department of Cardiology and Vascular Surgery

ivist08@yandex.ruhttps://orcid.org/0000-0002-3328-2812СтаростинаЕлена ГеоргиевнаStarostinaElena G.

д.м.н., профессор

MD, PhD, Professor

elena.starostina59@yandex.ruhttps://orcid.org/0000-0002-7936-7619АметовАлександр СергеевичAmetovAlexander S.

д.м.н., профессор

MD, PhD, Professor

alexander.ametov@gmail.comhttps://orcid.org/0000-0002-9944-2997АнциферовМихаил БорисовичAntsiferovMikhail B.

д.м.н., профессор

MD, PhD, Professor

antsiferov@rambler.ruhttps://orcid.org/0000-0003-4241-2217БардымоваТатьяна ПрокопьевнаBardymovaTatiana P.

д.м.н., профессор, заведующий кафедрой эндокринологии 

MD, PhD, Professor, Head of the Department of Endocrinology

tpbardymova@mail.ruhttps://orcid.org/0000-0003-4324-2926БондарьИрина АркадьевнаBondarIrina A.

д.м.н., проф.

MD, PhD, Professor

bondaria@oblmed.nsk.ruhttps://orcid.org/0000-0001-6000-8002ВалееваФарида ВадутовнаValeevaFarida V.

д.м.н., профессор

MD, PhD, Professor

val-farida@yandex.ruДемидоваТатьяна ЮльевнаDemidovaTatiana Y.

д.м.н., профессор

д.м.н., профессор

t.y.demidova@gmail.comhttps://orcid.org/0000-0003-1316-5245МкртумянАшот МусаеловичMkrtumyanAshot M.

д.м.н., профессор

MD, PhD, Professor

vagrashot@mail.ruhttps://orcid.org/0000-0001-9390-1200ПетунинаНина АлександровнаPetuninaNina A.

д.м.н., профессор

MD, PhD, Professor

napetunina@mail.ruhttps://orcid.org/0000-0002-6762-5238РуяткинаЛюдмила АлександровнаRuyatkinaLyudmila A.

д.м.н., профессор

MD, PhD, Professor

larut@list.ruhttps://orcid.org/0000-0001-9253-8075СуплотоваЛюдмила АлександровнаSuplotovaLyudmila A.

д.м.н., профессор

MD, ScD, professor

dr.suplotova@yahoo.comУшаковаОльга ВячеславовнаUshakovaOlga V.

.м.н., доцент кафедры общей врачебной практики и профилактической медицины

MD, Associate Professor, Department of General Medical Practice and Preventive Medicine

oluschk@mail.ruhttps://orcid.org/0000-0002-7755-7275ХалимовЮрий ШавкатовичKhalimovYurii Sh.

д.м.н., профессор, начальник кафедры и клиники военно-полевой терапии

MD, PhD, Professor

yushkha@gmail.comНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinological Research CentreRussian FederationМосковский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияMoscow Regional Research and Clinical InstituteRussian FederationРоссийская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Continuous Professional EducationRussian FederationЭндокринологический диспансер Департамента здравоохранения города МосквыРоссияMoscow Health Care Department, Endocrinology DispanseriumRussian FederationИркутская государственная медицинская академия последипломного образования – филиал Российской медицинской академии непрерывного профессионального образованияРоссияIrkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Russian Medical Academy of Continuing Professional EducationRussian FederationНовосибирский государственный медицинский университет Минздрава РоссииРоссияNovosibirsk State Medical UniversityRussian FederationКазанский государственный медицинский университет Минздрава РоссииРоссияKazan State Medical UniversityRussian FederationРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian FederationМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian FederationПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationНовосибирский государственный медицинский университетРоссияNovosibirsk State Medical UniversityRussian FederationФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава РоссииРоссияTyumen State Medical UniversityRussian FederationКГБОУ ДПО «Институт повышения квалификации специалистов здравоохранения» Министерства здравоохранения Хабаровского краяРоссияPostgraduate Institute for Public Health WorkersRussian FederationФГБВОУ ВО Военно-медицинская академия имени С.М. Кирова Министерства обороны РФРоссияMilitary Medical Academy of S.M. KirovRussian Federation202022062020232SКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ. САХАРНЫЙ ДИАБЕТ 2 ТИПА У ВЗРОСЛЫХ4102Copyright © Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р., Токмакова А.Ю., Никонова Т.В., Суркова Е.В., Кононенко И.В., Егорова Д.Н., Ибрагимова Л.И., Шестакова Е.А., Клефортова И.И., Скляник И.А., Ярек-Мартынова И.Я., Северина А.С., Мартынов С.А., Викулова О.К., Калашников В.Ю., Бондаренко И.З., Гомова И.С., Старостина Е.Г., Аметов А.С., Анциферов М.Б., Бардымова Т.П., Бондарь И.А., Валеева Ф.В., Демидова Т.Ю., Мкртумян А.М., Петунина Н.А., Руяткина Л.А., Суплотова Л.А., Ушакова О.В., Халимов Ю.Ш., 20202020Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р., Токмакова А.Ю., Никонова Т.В., Суркова Е.В., Кононенко И.В., Егорова Д.Н., Ибрагимова Л.И., Шестакова Е.А., Клефортова И.И., Скляник И.А., Ярек-Мартынова И.Я., Северина А.С., Мартынов С.А., Викулова О.К., Калашников В.Ю., Бондаренко И.З., Гомова И.С., Старостина Е.Г., Аметов А.С., Анциферов М.Б., Бардымова Т.П., Бондарь И.А., Валеева Ф.В., Демидова Т.Ю., Мкртумян А.М., Петунина Н.А., Руяткина Л.А., Суплотова Л.А., Ушакова О.В., Халимов Ю.Ш.Dedov I.I., Shestakova M.V., Mayorov A.Y., Shamkhalova M.S., Sukhareva O.Y., Galstyan G.R., Tokmakova A.Y., Nikonova T.V., Surkova E.V., Kononenko I.V., Egorova D.N., Ibragimova L.I., Shestakova E.A., Klefortova I.I., Sklyanik I.A., Yarek-Martynova I.Y., Severina A.S., Martynov S.A., Vikulova O.K., Kalashnikov V.Y., Bondarenko I.Z., Gomova I.S., Starostina E.G., Ametov A.S., Antsiferov M.B., Bardymova T.P., Bondar I.A., Valeeva F.V., Demidova T.Y., Mkrtumyan A.M., Petunina N.A., Ruyatkina L.A., Suplotova L.A., Ushakova O.V., Khalimov Y.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12507

Общественная организация «Российская ассоциация эндокринологов». Клинические рекомендации.

Public organization “Russian Association of Endocrinologists”. Clinical guidelines. 

сахарный диабет 2 типавзрослыеклинические рекомендацииtype 2 diabetes mellitusadultsclinical guidlinesReferencesWorld Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. Geneva; 2006;World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. Geneva; 2006;World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva; 1999;World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva; 1999;Дедов ИИ, Шестакова МВ, Майоров АЮ, Викулова ОК, Галстян ГР, Кураева ТЛ, et al. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 9-й выпуск. Сахарный диабет [Internet]. 2019;22(1S). doi: 10.14341/DM221S1Дедов ИИ, Шестакова МВ, Майоров АЮ, Викулова ОК, Галстян ГР, Кураева ТЛ, et al. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 9-й выпуск. Сахарный диабет [Internet]. 2019;22(1S). doi: 10.14341/DM221S1Дедов ИИ, Шестакова МВ. Сахарный диабет типа 2: от теории к практике. МИА; 2016; 576 p.Дедов ИИ, Шестакова МВ. Сахарный диабет типа 2: от теории к практике. МИА; 2016; 576 p.Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care. 2016;39(2):179–186. doi: 10.2337/dc15-1585Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care. 2016;39(2):179–186. doi: 10.2337/dc15-1585International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels: IDF; 2017; 148 p.International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels: IDF; 2017; 148 p.Дедов ИИ, Шестакова МВ, Галстян ГР. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет [Internet]. 2016;19(2):104–112. doi: 10.14341/DM2004116-17Дедов ИИ, Шестакова МВ, Галстян ГР. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет [Internet]. 2016;19(2):104–112. doi: 10.14341/DM2004116-17World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva; 2013;World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva; 2013;American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S13–S28. doi: 10.2337/dc19-S002American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S13–S28. doi: 10.2337/dc19-S002World Health Organization, International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia [Internet]. Geneva; 2006; 50 p.World Health Organization, International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia [Internet]. Geneva; 2006; 50 p.World Health Organization. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva; 2011;World Health Organization. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva; 2011;Дедов ИИ, Шестакова МВ. Сахарный диабет: диагностика, лечение, профилактика. Москва: МИА; 2011; 808 p.Дедов ИИ, Шестакова МВ. Сахарный диабет: диагностика, лечение, профилактика. Москва: МИА; 2011; 808 p.Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222–232. doi: 10.1038/nrendo.2016.15Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222–232. doi: 10.1038/nrendo.2016.15American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S34–S45. doi: 10.2337/dc19-S004American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S34–S45. doi: 10.2337/dc19-S004National Kidney Foundation. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl [Internet]. 2013;3(1):1–150.National Kidney Foundation. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl [Internet]. 2013;3(1):1–150.Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol (Chicago, Ill 1960). 1984;102(4):527–532.Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol (Chicago, Ill 1960). 1984;102(4):527–532.Klein R. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 1989;107(2):244–249. doi: 10.1001/archopht.1989.01070010250031Klein R. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 1989;107(2):244–249. doi: 10.1001/archopht.1989.01070010250031American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S124–S138. doi: 10.2337/dc19-S011American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S124–S138. doi: 10.2337/dc19-S011Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic Somatic Neuropathies. Diabetes Care. 2004;27(6):1458–1486. doi: 10.2337/diacare.27.6.1458Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic Somatic Neuropathies. Diabetes Care. 2004;27(6):1458–1486. doi: 10.2337/diacare.27.6.1458England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et al. Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64(2):199–207. doi: 10.1212/01.WNL.0000149522.32823.EAEngland JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et al. Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64(2):199–207. doi: 10.1212/01.WNL.0000149522.32823.EAHingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2):3S-21S. doi: 10.1016/j.jvs.2015.10.003Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2):3S-21S. doi: 10.1016/j.jvs.2015.10.003Hart T, Milner R, Cifu A. Management of a Diabetic Foot. JAMA. 2017;318(14):1387–1388. doi: 10.1001/jama.2017.11700Hart T, Milner R, Cifu A. Management of a Diabetic Foot. JAMA. 2017;318(14):1387–1388. doi: 10.1001/jama.2017.11700González-Lao E, Corte Z, Simón M, Ricós C, Coskun A, Braga F, et al. Systematic review of the biological variation data for diabetes related analytes. Clin Chim Acta. 2019;488:61–67. doi: 10.1016/j.cca.2018.10.031González-Lao E, Corte Z, Simón M, Ricós C, Coskun A, Braga F, et al. Systematic review of the biological variation data for diabetes related analytes. Clin Chim Acta. 2019;488:61–67. doi: 10.1016/j.cca.2018.10.031Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017;8(3):475–487. doi: 10.1007/s13300-017-0265-4Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017;8(3):475–487. doi: 10.1007/s13300-017-0265-4Силко ЮВ, Никонова ТВ, Иванова ОН, Степанова СМ, Шестакова МВ, Дедов ИИ. Латентный аутоиммунный диабет взрослых: информативность аутоантител. Терапевтический архив (архив до 2018 г) [Internet]. 2016;88(10):42–45. doi: 10.17116/terarkh2016881042-45Силко ЮВ, Никонова ТВ, Иванова ОН, Степанова СМ, Шестакова МВ, Дедов ИИ. Латентный аутоиммунный диабет взрослых: информативность аутоантител. Терапевтический архив (архив до 2018 г) [Internet]. 2016;88(10):42–45. doi: 10.17116/terarkh2016881042-45Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013;36(9):2615–2620. doi: 10.2337/dc13-0425Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013;36(9):2615–2620. doi: 10.2337/dc13-0425Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504–2508. doi: 10.1007/s00125-010-1799-4Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504–2508. doi: 10.1007/s00125-010-1799-4Shepherd M, Sparkes AC, Hattersley AT. Genetic testing in maturity onset diabetes of the young (MODY): a new challenge for the diabetic clinic. Pract Diabetes Int. 2001;18(1):16–21. doi: 10.1002/pdi.108Shepherd M, Sparkes AC, Hattersley AT. Genetic testing in maturity onset diabetes of the young (MODY): a new challenge for the diabetic clinic. Pract Diabetes Int. 2001;18(1):16–21. doi: 10.1002/pdi.108Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):911–917. doi: 10.2337/dc06-1426Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):911–917. doi: 10.2337/dc06-1426Tajar A, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508–1516. doi: 10.1210/jc.2011-2513Tajar A, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508–1516. doi: 10.1210/jc.2011-2513Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen T-P, Haring R, et al. Testosterone, Sex Hormone-Binding Globulin and the Metabolic Syndrome in Men: An Individual Participant Data Meta-Analysis of Observational Studies. Cignarella A, editor. PLoS One. 2014;9(7):e100409. doi: 10.1371/journal.pone.0100409Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen T-P, Haring R, et al. Testosterone, Sex Hormone-Binding Globulin and the Metabolic Syndrome in Men: An Individual Participant Data Meta-Analysis of Observational Studies. Cignarella A, editor. PLoS One. 2014;9(7):e100409. doi: 10.1371/journal.pone.0100409EAU Guidelines. Edn. presented at the EAU Annual Congress London 2017.EAU Guidelines. Edn. presented at the EAU Annual Congress London 2017.Дедов ИИ, Мельниченко ГА, Шестакова МВ, Роживанов РВ, Терехова АЛ, Зилов АВ, et al. Рекомендации по диагностике и лечению дефицита тестостерона (гипогонадизма) у мужчинс сахарным диабетом. Ожирение и метаболизм [Internet]. 2017;14(4):83–92. doi: 10.14341/DM9944Дедов ИИ, Мельниченко ГА, Шестакова МВ, Роживанов РВ, Терехова АЛ, Зилов АВ, et al. Рекомендации по диагностике и лечению дефицита тестостерона (гипогонадизма) у мужчинс сахарным диабетом. Ожирение и метаболизм [Internet]. 2017;14(4):83–92. doi: 10.14341/DM9944Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298–2307. doi: 10.1007/s00125-016-4065-6Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298–2307. doi: 10.1007/s00125-016-4065-6UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360(2):129–139. doi: 10.1056/NEJMoa0808431Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360(2):129–139. doi: 10.1056/NEJMoa0808431ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: 10.1056/NEJMoa0802987ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: 10.1056/NEJMoa0802987Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology. Diabetes Care. 2009;32(1):187–192. doi: 10.2337/dc08-9026Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology. Diabetes Care. 2009;32(1):187–192. doi: 10.2337/dc08-9026Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров АЮ, et al. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет [Internet]. 2011;14(4):6–17. doi: 10.14341/2072-0351-5810Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров АЮ, et al. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет [Internet]. 2011;14(4):6–17. doi: 10.14341/2072-0351-5810Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–1596. doi: 10.1007/s00125-012-2534-0Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–1596. doi: 10.1007/s00125-012-2534-0Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care. 2016;39(7):1089–1100. doi: 10.2337/dc16-0024Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care. 2016;39(7):1089–1100. doi: 10.2337/dc16-0024Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C Assay Into Estimated Average Glucose Values. Diabetes Care. 2008;31(8):1473–1478. doi: 10.2337/dc08-0545Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C Assay Into Estimated Average Glucose Values. Diabetes Care. 2008;31(8):1473–1478. doi: 10.2337/dc08-0545Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696. doi: 10.1016/S0140-6736(04)16895-5Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696. doi: 10.1016/S0140-6736(04)16895-5Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125. doi: 10.1016/S0140-6736(08)60104-XCholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125. doi: 10.1016/S0140-6736(08)60104-XBaigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278. doi: 10.1016/S0140-6736(05)67394-1Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278. doi: 10.1016/S0140-6736(05)67394-1Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi: 10.1093/eurheartj/ehw272Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi: 10.1093/eurheartj/ehw272Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405. doi: 10.1016/S0140-6736(14)61368-4Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405. doi: 10.1016/S0140-6736(14)61368-4Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi: 10.1016/S0140-6736(10)61350-5ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. doi: 10.1056/NEJMoa0801317ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. doi: 10.1056/NEJMoa0801317Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. J Hypertens. 2017;35(5):922–944. doi: 10.1097/HJH.0000000000001276Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. J Hypertens. 2017;35(5):922–944. doi: 10.1097/HJH.0000000000001276Grenier J, Goodman SG, Leiter LA, Langer A, Teoh H, Bhatt DL, et al. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Can J Diabetes. 2018;42(2):130–137. doi: 10.1016/j.jcjd.2017.01.005Grenier J, Goodman SG, Leiter LA, Langer A, Teoh H, Bhatt DL, et al. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Can J Diabetes. 2018;42(2):130–137. doi: 10.1016/j.jcjd.2017.01.005ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585. doi: 10.1056/NEJMoa1001286ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585. doi: 10.1056/NEJMoa1001286ГОСТ Р ИСО 15197-2015 Тест-системы для диагностики in vitro. Требования к системам мониторинга глюкозы в крови для самоконтроля при лечении сахарного диабета. Москва: Стандартинформ; 2015; 41 p.ГОСТ Р ИСО 15197-2015 Тест-системы для диагностики in vitro. Требования к системам мониторинга глюкозы в крови для самоконтроля при лечении сахарного диабета. Москва: Стандартинформ; 2015; 41 p.American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S61–S70. doi: 10.2337/dc19-S006American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S61–S70. doi: 10.2337/dc19-S006Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577–1589. doi: 10.1056/NEJMoa0806470Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577–1589. doi: 10.1056/NEJMoa0806470Sheppard P, Bending J, Huber J. Pre- and post-prandial capillary glucose self-monitoring achieves better glycaemic control than pre-prandial only monitoring. Pract Diabetes Int. 2005;22(1):15–22. doi: 10.1002/pdi.733Sheppard P, Bending J, Huber J. Pre- and post-prandial capillary glucose self-monitoring achieves better glycaemic control than pre-prandial only monitoring. Pract Diabetes Int. 2005;22(1):15–22. doi: 10.1002/pdi.733Boutati EI, Raptis SA. Self-Monitoring of Blood Glucose as Part of the Integral Care of Type 2 Diabetes. Diabetes Care. 2009;32(suppl_2):S205–S210. doi: 10.2337/dc09-S312Boutati EI, Raptis SA. Self-Monitoring of Blood Glucose as Part of the Integral Care of Type 2 Diabetes. Diabetes Care. 2009;32(suppl_2):S205–S210. doi: 10.2337/dc09-S312Harris MI. Frequency of Blood Glucose Monitoring in Relation to Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care. 2001;24(6):979–982. doi: 10.2337/diacare.24.6.979Harris MI. Frequency of Blood Glucose Monitoring in Relation to Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care. 2001;24(6):979–982. doi: 10.2337/diacare.24.6.979Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Self-monitoring in Type 2 diabetes mellitus: a meta-analysis. Diabet Med. 2000;17(11):755–761.Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Self-monitoring in Type 2 diabetes mellitus: a meta-analysis. Diabet Med. 2000;17(11):755–761.Welschen LMC, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WAB, et al. Self-Monitoring of Blood Glucose in Patients With Type 2 Diabetes Who Are Not Using Insulin: A systematic review. Diabetes Care. 2005;28(6):1510–1517. doi: 10.2337/diacare.28.6.1510Welschen LMC, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WAB, et al. Self-Monitoring of Blood Glucose in Patients With Type 2 Diabetes Who Are Not Using Insulin: A systematic review. Diabetes Care. 2005;28(6):1510–1517. doi: 10.2337/diacare.28.6.1510Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: A blinded, randomized trial. Am J Med. 2005;118(4):422–425. doi: 10.1016/j.amjmed.2004.12.006Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: A blinded, randomized trial. Am J Med. 2005;118(4):422–425. doi: 10.1016/j.amjmed.2004.12.006Davis WA, Bruce DG, Davis TME. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia. 2007;50(3):510–515. doi: 10.1007/s00125-006-0581-0Davis WA, Bruce DG, Davis TME. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia. 2007;50(3):510–515. doi: 10.1007/s00125-006-0581-0Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ. 2007;335(7611):132. doi: 10.1136/bmj.39247.447431.BEFarmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ. 2007;335(7611):132. doi: 10.1136/bmj.39247.447431.BEAllemann S, Houriet C, Diem P, Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Curr Med Res Opin. 2009;25(12):2903–2913. doi: 10.1185/03007990903364665Allemann S, Houriet C, Diem P, Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Curr Med Res Opin. 2009;25(12):2903–2913. doi: 10.1185/03007990903364665Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus:a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006;22(4):671–681. doi: 10.1185/030079906X96308Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus:a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006;22(4):671–681. doi: 10.1185/030079906X96308McGeoch G, Derry S, Moore RA. Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? Diabetes Metab Res Rev. 2007;23(6):423–440. doi: 10.1002/dmrr.749McGeoch G, Derry S, Moore RA. Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? Diabetes Metab Res Rev. 2007;23(6):423–440. doi: 10.1002/dmrr.749Poolsup N, Suksomboon N, Rattanasookchit S. Meta-Analysis of the Benefits of Self-Monitoring of Blood Glucose on Glycemic Control in Type 2 Diabetes Patients: An Update. Diabetes Technol Ther. 2009;11(12):775–784. doi: 10.1089/dia.2009.0091Poolsup N, Suksomboon N, Rattanasookchit S. Meta-Analysis of the Benefits of Self-Monitoring of Blood Glucose on Glycemic Control in Type 2 Diabetes Patients: An Update. Diabetes Technol Ther. 2009;11(12):775–784. doi: 10.1089/dia.2009.0091St John A, Davis WA, Price CP, Davis TME. The value of self-monitoring of blood glucose: a review of recent evidence. J Diabetes Complications. 2010;24(2):129–141. doi: 10.1016/j.jdiacomp.2009.01.002St John A, Davis WA, Price CP, Davis TME. The value of self-monitoring of blood glucose: a review of recent evidence. J Diabetes Complications. 2010;24(2):129–141. doi: 10.1016/j.jdiacomp.2009.01.002Towfigh A, Romanova M, Weinreb JE, Munjas B, Suttorp MJ, Zhou A, et al. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis. Am J Manag Care. 2008;14(7):468–475.Towfigh A, Romanova M, Weinreb JE, Munjas B, Suttorp MJ, Zhou A, et al. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis. Am J Manag Care. 2008;14(7):468–475.Ham P. Glycemic control in the hospital: what to do when experts disagree. Am Fam Physician. 2010;81(9):1078.Ham P. Glycemic control in the hospital: what to do when experts disagree. Am Fam Physician. 2010;81(9):1078.Lewandrowski K. Point-of-care testing: an overview and a look to the future (circa 2009, United States). Clin Lab Med. 2009;29(3):421–432. doi: 10.1016/j.cll.2009.06.015Lewandrowski K. Point-of-care testing: an overview and a look to the future (circa 2009, United States). Clin Lab Med. 2009;29(3):421–432. doi: 10.1016/j.cll.2009.06.015Klonoff DC, Perz JF. Assisted Monitoring of Blood Glucose: Special Safety Needs for a New Paradigm in Testing Glucose. J Diabetes Sci Technol. 2010;4(5):1027–1031. doi: 10.1177/193229681000400501Klonoff DC, Perz JF. Assisted Monitoring of Blood Glucose: Special Safety Needs for a New Paradigm in Testing Glucose. J Diabetes Sci Technol. 2010;4(5):1027–1031. doi: 10.1177/193229681000400501World Health Organization. WHO injection safety. Fact sheet No. 231. Revised May 2016. Geneva; 2016;World Health Organization. WHO injection safety. Fact sheet No. 231. Revised May 2016. Geneva; 2016;Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Technol. 2009;3(2):283–288. doi: 10.1177/193229680900300208Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Technol. 2009;3(2):283–288. doi: 10.1177/193229680900300208Jovanovic L, Savas H, Mehta M, Trujillo A, Pettitt DJ. Frequent Monitoring of A1C During Pregnancy as a Treatment Tool to Guide Therapy. Diabetes Care. 2011;34(1):53–54. doi: 10.2337/dc10-1455Jovanovic L, Savas H, Mehta M, Trujillo A, Pettitt DJ. Frequent Monitoring of A1C During Pregnancy as a Treatment Tool to Guide Therapy. Diabetes Care. 2011;34(1):53–54. doi: 10.2337/dc10-1455Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48(3):436–472.Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48(3):436–472.American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA1c measurement. Diabetologia. 2007;50(10):2042–2043. doi: 10.1007/s00125-007-0789-7American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, International Diabetes Federation. Consensus statement on the worldwide standardisation of the HbA1c measurement. Diabetologia. 2007;50(10):2042–2043. doi: 10.1007/s00125-007-0789-7Driskell OJ, Holland D, Waldron JL, Ford C, Scargill JJ, Heald A, et al. Reduced Testing Frequency for Glycated Hemoglobin, HbA 1c, Is Associated With Deteriorating Diabetes Control. Diabetes Care. 2014;37(10):2731–2737. doi: 10.2337/dc14-0297Driskell OJ, Holland D, Waldron JL, Ford C, Scargill JJ, Heald A, et al. Reduced Testing Frequency for Glycated Hemoglobin, HbA 1c, Is Associated With Deteriorating Diabetes Control. Diabetes Care. 2014;37(10):2731–2737. doi: 10.2337/dc14-0297Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the Inte. Diabetes Care. 2007;30(9):2399–2400. doi: 10.2337/dc07-9925Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the Inte. Diabetes Care. 2007;30(9):2399–2400. doi: 10.2337/dc07-9925Sacks DB. Measurement of Hemoglobin A1c: A new twist on the path to harmony. Diabetes Care. 2012;35(12):2674–2680. doi: 10.2337/dc12-1348Sacks DB. Measurement of Hemoglobin A1c: A new twist on the path to harmony. Diabetes Care. 2012;35(12):2674–2680. doi: 10.2337/dc12-1348Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631–1640. doi: 10.2337/dc17-1600Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631–1640. doi: 10.2337/dc17-1600Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–1603. doi: 10.2337/dci19-0028Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–1603. doi: 10.2337/dci19-0028Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther. 2017;8(1):55–73. doi: 10.1007/s13300-016-0223-6Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther. 2017;8(1):55–73. doi: 10.1007/s13300-016-0223-6Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017;167(6):365–374. doi: 10.7326/M16-2855Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017;167(6):365–374. doi: 10.7326/M16-2855Carlson AL, Mullen DM, Bergenstal RM. Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. Diabetes Technol Ther. 2017;19(S2):S4–S11. doi: 10.1089/dia.2017.0024Carlson AL, Mullen DM, Bergenstal RM. Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. Diabetes Technol Ther. 2017;19(S2):S4–S11. doi: 10.1089/dia.2017.0024Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. Diabetes Vasc Dis Res. 2019;16(1):3–12. doi: 10.1177/1479164118795252Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. Diabetes Vasc Dis Res. 2019;16(1):3–12. doi: 10.1177/1479164118795252Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition Therapy Recommendations for the Management of Adults With Diabetes. Diabetes Care. 2014;37(Supplement_1):S120–S143. doi: 10.2337/dc14-S120Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition Therapy Recommendations for the Management of Adults With Diabetes. Diabetes Care. 2014;37(Supplement_1):S120–S143. doi: 10.2337/dc14-S120Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi: 10.2337/dci18-0033Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi: 10.2337/dci18-0033MacLeod J, Franz MJ, Handu D, Gradwell E, Brown C, Evert A, et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Nutrition Intervention Evidence Reviews and Recommendations. J Acad Nutr Diet. 2017;117(10):1637–1658. doi: 10.1016/j.jand.2017.03.023MacLeod J, Franz MJ, Handu D, Gradwell E, Brown C, Evert A, et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Nutrition Intervention Evidence Reviews and Recommendations. J Acad Nutr Diet. 2017;117(10):1637–1658. doi: 10.1016/j.jand.2017.03.023Mudaliar U, Zabetian A, Goodman M, Echouffo-Tcheugui JB, Albright AL, Gregg EW, et al. Cardiometabolic Risk Factor Changes Observed in Diabetes Prevention Programs in US Settings: A Systematic Review and Meta-analysis. Wareham NJ, editor. PLOS Med. 2016;13(7):e1002095. doi: 10.1371/journal.pmed.1002095Mudaliar U, Zabetian A, Goodman M, Echouffo-Tcheugui JB, Albright AL, Gregg EW, et al. Cardiometabolic Risk Factor Changes Observed in Diabetes Prevention Programs in US Settings: A Systematic Review and Meta-analysis. Wareham NJ, editor. PLOS Med. 2016;13(7):e1002095. doi: 10.1371/journal.pmed.1002095Balk EM, Earley A, Raman G, Avendano EA, Pittas AG, Remington PL. Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. Ann Intern Med. 2015;163(6):437–451. doi: 10.7326/M15-0452Balk EM, Earley A, Raman G, Avendano EA, Pittas AG, Remington PL. Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. Ann Intern Med. 2015;163(6):437–451. doi: 10.7326/M15-0452Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle Weight-Loss Intervention Outcomes in Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Acad Nutr Diet. 2015;115(9):1447–1463. doi: 10.1016/j.jand.2015.02.031Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle Weight-Loss Intervention Outcomes in Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Acad Nutr Diet. 2015;115(9):1447–1463. doi: 10.1016/j.jand.2015.02.031Schwingshackl L, Chaimani A, Hoffmann G, Schwedhelm C, Boeing H. A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol. 2018;33(2):157–170. doi: 10.1007/s10654-017-0352-xSchwingshackl L, Chaimani A, Hoffmann G, Schwedhelm C, Boeing H. A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol. 2018;33(2):157–170. doi: 10.1007/s10654-017-0352-xTrumbo P, Schlicker S, Yates AA, Poos M, Food and Nutrition Board of the Institute of Medicine TNA. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002;102(11):1621–1630.Trumbo P, Schlicker S, Yates AA, Poos M, Food and Nutrition Board of the Institute of Medicine TNA. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002;102(11):1621–1630.Hamdy O, Mottalib A, Morsi A, El-Sayed N, Goebel-Fabbri A, Arathuzik G, et al. Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study. BMJ Open Diabetes Res Care. 2017;5(1):e000259. doi: 10.1136/bmjdrc-2016-000259Hamdy O, Mottalib A, Morsi A, El-Sayed N, Goebel-Fabbri A, Arathuzik G, et al. Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study. BMJ Open Diabetes Res Care. 2017;5(1):e000259. doi: 10.1136/bmjdrc-2016-000259Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–551. doi: 10.1016/S0140-6736(17)33102-1Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–551. doi: 10.1016/S0140-6736(17)33102-1Mottalib A, Salsberg V, Mohd-Yusof B-N, Mohamed W, Carolan P, Pober DM, et al. Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. Nutr J. 2018;17(1):42. doi: 10.1186/s12937-018-0351-0Mottalib A, Salsberg V, Mohd-Yusof B-N, Mohamed W, Carolan P, Pober DM, et al. Effects of nutrition therapy on HbA1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. Nutr J. 2018;17(1):42. doi: 10.1186/s12937-018-0351-0Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi: 10.1056/NEJMoa1800389Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi: 10.1056/NEJMoa1800389Saslow LR, Daubenmier JJ, Moskowitz JT, Kim S, Murphy EJ, Phinney SD, et al. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. Nutr Diabetes. 2017;7(12):304. doi: 10.1038/s41387-017-0006-9Saslow LR, Daubenmier JJ, Moskowitz JT, Kim S, Murphy EJ, Phinney SD, et al. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. Nutr Diabetes. 2017;7(12):304. doi: 10.1038/s41387-017-0006-9Emadian A, Andrews RC, England CY, Wallace V, Thompson JL. The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. Br J Nutr. 2015;114(10):1656–1666. doi: 10.1017/S0007114515003475Emadian A, Andrews RC, England CY, Wallace V, Thompson JL. The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. Br J Nutr. 2015;114(10):1656–1666. doi: 10.1017/S0007114515003475Gardner CD, Trepanowski JF, Del Gobbo LC, Hauser ME, Rigdon J, Ioannidis JPA, et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion. JAMA. 2018;319(7):667–679. doi: 10.1001/jama.2018.0245Gardner CD, Trepanowski JF, Del Gobbo LC, Hauser ME, Rigdon J, Ioannidis JPA, et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion. JAMA. 2018;319(7):667–679. doi: 10.1001/jama.2018.0245Schwingshackl L, Schwedhelm C, Hoffmann G, Lampousi A-M, Knüppel S, Iqbal K, et al. Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2017;105(6):1462–1473. doi: 10.3945/ajcn.117.153148Schwingshackl L, Schwedhelm C, Hoffmann G, Lampousi A-M, Knüppel S, Iqbal K, et al. Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2017;105(6):1462–1473. doi: 10.3945/ajcn.117.153148Grotz VL, Pi-Sunyer X, Porte D, Roberts A, Richard Trout J. A 12-week randomized clinical trial investigating the potential for sucralose to affect glucose homeostasis. Regul Toxicol Pharmacol. 2017;88:22–33. doi: 10.1016/j.yrtph.2017.05.011Grotz VL, Pi-Sunyer X, Porte D, Roberts A, Richard Trout J. A 12-week randomized clinical trial investigating the potential for sucralose to affect glucose homeostasis. Regul Toxicol Pharmacol. 2017;88:22–33. doi: 10.1016/j.yrtph.2017.05.011Miller PE, Perez V. Low-calorie sweeteners and body weight and composition: a meta-analysis of randomized controlled trials and prospective cohort studies. Am J Clin Nutr. 2014;100(3):765–777. doi: 10.3945/ajcn.113.082826Miller PE, Perez V. Low-calorie sweeteners and body weight and composition: a meta-analysis of randomized controlled trials and prospective cohort studies. Am J Clin Nutr. 2014;100(3):765–777. doi: 10.3945/ajcn.113.082826Rogers PJ, Hogenkamp PS, de Graaf C, Higgs S, Lluch A, Ness AR, et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. Int J Obes. 2016;40(3):381–394. doi: 10.1038/ijo.2015.177Rogers PJ, Hogenkamp PS, de Graaf C, Higgs S, Lluch A, Ness AR, et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. Int J Obes. 2016;40(3):381–394. doi: 10.1038/ijo.2015.177Franz MJ, MacLeod J, Evert A, Brown C, Gradwell E, Handu D, et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Systematic Review of Evidence for Medical Nutrition Therapy Effectiveness and Recommendations for Integration into the Nutrition Care Process. J Acad Nutr Diet. 2017;117(10):1659–1679. doi: 10.1016/j.jand.2017.03.022Franz MJ, MacLeod J, Evert A, Brown C, Gradwell E, Handu D, et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Systematic Review of Evidence for Medical Nutrition Therapy Effectiveness and Recommendations for Integration into the Nutrition Care Process. J Acad Nutr Diet. 2017;117(10):1659–1679. doi: 10.1016/j.jand.2017.03.022Bowen ME, Cavanaugh KL, Wolff K, Davis D, Gregory RP, Shintani A, et al. The diabetes nutrition education study randomized controlled trial: A comparative effectiveness study of approaches to nutrition in diabetes self-management education. Patient Educ Couns. 2016;99(8):1368–1376. doi: 10.1016/j.pec.2016.03.017Bowen ME, Cavanaugh KL, Wolff K, Davis D, Gregory RP, Shintani A, et al. The diabetes nutrition education study randomized controlled trial: A comparative effectiveness study of approaches to nutrition in diabetes self-management education. Patient Educ Couns. 2016;99(8):1368–1376. doi: 10.1016/j.pec.2016.03.017Savoca MR, Miller CK, Ludwig DA. Food habits are related to glycemic control among people with type 2 diabetes mellitus. J Am Diet Assoc. 2004;104(4):560–566. doi: 10.1016/j.jada.2004.01.013Savoca MR, Miller CK, Ludwig DA. Food habits are related to glycemic control among people with type 2 diabetes mellitus. J Am Diet Assoc. 2004;104(4):560–566. doi: 10.1016/j.jada.2004.01.013Arnold L, Mann JI, Ball MJ. Metabolic effects of alterations in meal frequency in type 2 diabetes. Diabetes Care. 1997;20(11):1651–1654. doi: 10.2337/diacare.20.11.1651Arnold L, Mann JI, Ball MJ. Metabolic effects of alterations in meal frequency in type 2 diabetes. Diabetes Care. 1997;20(11):1651–1654. doi: 10.2337/diacare.20.11.1651Marran KJ, Davey B, Lang A, Segal DG. Exponential increase in postprandial blood-glucose exposure with increasing carbohydrate loads using a linear carbohydrate-to-insulin ratio. South African Med J. 2013;103(7):461–463. doi: 10.7196/samj.6382Marran KJ, Davey B, Lang A, Segal DG. Exponential increase in postprandial blood-glucose exposure with increasing carbohydrate loads using a linear carbohydrate-to-insulin ratio. South African Med J. 2013;103(7):461–463. doi: 10.7196/samj.6382Rossi MCE, Nicolucci A, Di Bartolo P, Bruttomesso D, Girelli A, Ampudia FJ, et al. Diabetes Interactive Diary: A New Telemedicine System Enabling Flexible Diet and Insulin Therapy While Improving Quality of Life: An open-label, international, multicenter, randomized study. Diabetes Care. 2010;33(1):109–115. doi: 10.2337/dc09-1327Rossi MCE, Nicolucci A, Di Bartolo P, Bruttomesso D, Girelli A, Ampudia FJ, et al. Diabetes Interactive Diary: A New Telemedicine System Enabling Flexible Diet and Insulin Therapy While Improving Quality of Life: An open-label, international, multicenter, randomized study. Diabetes Care. 2010;33(1):109–115. doi: 10.2337/dc09-1327Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31(7):1305–1310. doi: 10.2337/dc07-2137Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31(7):1305–1310. doi: 10.2337/dc07-2137Tunbridge FK, Home PD, Murphy M, Alberti KG. Does flexibility at mealtimes disturb blood glucose control on a multiple insulin injection regimen? Diabet Med. 1991;8(9):833–838. doi: 10.1111/j.1464-5491.1991.tb02121.xTunbridge FK, Home PD, Murphy M, Alberti KG. Does flexibility at mealtimes disturb blood glucose control on a multiple insulin injection regimen? Diabet Med. 1991;8(9):833–838. doi: 10.1111/j.1464-5491.1991.tb02121.xHuckvale K, Adomaviciute S, Prieto JT, Leow MK-S, Car J. Smartphone apps for calculating insulin dose: a systematic assessment. BMC Med. 2015;13(1):106. doi: 10.1186/s12916-015-0314-7Huckvale K, Adomaviciute S, Prieto JT, Leow MK-S, Car J. Smartphone apps for calculating insulin dose: a systematic assessment. BMC Med. 2015;13(1):106. doi: 10.1186/s12916-015-0314-7U.S. Department of Health and Human Services, U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 8th Edition. Washington; 2015;U.S. Department of Health and Human Services, U.S. Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 8th Edition. Washington; 2015;Hegde S V., Adhikari P, M N, D’Souza V. Effect of daily supplementation of fruits on oxidative stress indices and glycaemic status in type 2 diabetes mellitus. Complement Ther Clin Pract. 2013;19(2):97–100. doi: 10.1016/j.ctcp.2012.12.002Hegde S V., Adhikari P, M N, D’Souza V. Effect of daily supplementation of fruits on oxidative stress indices and glycaemic status in type 2 diabetes mellitus. Complement Ther Clin Pract. 2013;19(2):97–100. doi: 10.1016/j.ctcp.2012.12.002Shin JY, Kim JY, Kang HT, Han KH, Shim JY. Effect of fruits and vegetables on metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Int J Food Sci Nutr. 2015;66(4):416–425. doi: 10.3109/09637486.2015.1025716Shin JY, Kim JY, Kang HT, Han KH, Shim JY. Effect of fruits and vegetables on metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Int J Food Sci Nutr. 2015;66(4):416–425. doi: 10.3109/09637486.2015.1025716Petersen KS, Clifton PM, Blanch N, Keogh JB. Effect of improving dietary quality on carotid intima media thickness in subjects with type 1 and type 2 diabetes: a 12-mo randomized controlled trial. Am J Clin Nutr. 2015;102(4):771–779. doi: 10.3945/ajcn.115.112151Petersen KS, Clifton PM, Blanch N, Keogh JB. Effect of improving dietary quality on carotid intima media thickness in subjects with type 1 and type 2 diabetes: a 12-mo randomized controlled trial. Am J Clin Nutr. 2015;102(4):771–779. doi: 10.3945/ajcn.115.112151Viguiliouk E, Kendall CWC, Blanco Mejia S, Cozma AI, Ha V, Mirrahimi A, et al. Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials. PLoS One. 2014;9(7):e103376. doi: 10.1371/journal.pone.0103376Viguiliouk E, Kendall CWC, Blanco Mejia S, Cozma AI, Ha V, Mirrahimi A, et al. Effect of tree nuts on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled dietary trials. PLoS One. 2014;9(7):e103376. doi: 10.1371/journal.pone.0103376Hollænder PLB, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr. 2015;102(3):556–572. doi: 10.3945/ajcn.115.109165Hollænder PLB, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr. 2015;102(3):556–572. doi: 10.3945/ajcn.115.109165Te Morenga LA, Howatson AJ, Jones RM, Mann J. Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids. Am J Clin Nutr. 2014;100(1):65–79. doi: 10.3945/ajcn.113.081521Te Morenga LA, Howatson AJ, Jones RM, Mann J. Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids. Am J Clin Nutr. 2014;100(1):65–79. doi: 10.3945/ajcn.113.081521Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2014;349:g4490. doi: 10.1136/bmj.g4490Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2014;349:g4490. doi: 10.1136/bmj.g4490Ekinci EI, Clarke S, Thomas MC, Moran JL, Cheong K, MacIsaac RJ, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34(3):703–709. doi: 10.2337/dc10-1723Ekinci EI, Clarke S, Thomas MC, Moran JL, Cheong K, MacIsaac RJ, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34(3):703–709. doi: 10.2337/dc10-1723Azadbakht L, Fard NRP, Karimi M, Baghaei MH, Surkan PJ, Rahimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011;34(1):55–57. doi: 10.2337/dc10-0676Azadbakht L, Fard NRP, Karimi M, Baghaei MH, Surkan PJ, Rahimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011;34(1):55–57. doi: 10.2337/dc10-0676Chiavaroli L, de Souza RJ, Ha V, Cozma AI, Mirrahimi A, Wang DD, et al. Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. J Am Heart Assoc. 2015;4(9):e001700. doi: 10.1161/JAHA.114.001700Chiavaroli L, de Souza RJ, Ha V, Cozma AI, Mirrahimi A, Wang DD, et al. Effect of Fructose on Established Lipid Targets: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. J Am Heart Assoc. 2015;4(9):e001700. doi: 10.1161/JAHA.114.001700Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity. Circulation. 2016;133(2):187–225. doi: 10.1161/CIRCULATIONAHA.115.018585Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity. Circulation. 2016;133(2):187–225. doi: 10.1161/CIRCULATIONAHA.115.018585Blomster JI, Zoungas S, Chalmers J, Li Q, Chow CK, Woodward M, et al. The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. Diabetes Care. 2014;37(5):1353–1359. doi: 10.2337/dc13-2727Blomster JI, Zoungas S, Chalmers J, Li Q, Chow CK, Woodward M, et al. The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. Diabetes Care. 2014;37(5):1353–1359. doi: 10.2337/dc13-2727Ahmed AT, Karter AJ, Warton EM, Doan JU, Weisner CM. The relationship between alcohol consumption and glycemic control among patients with diabetes: the Kaiser Permanente Northern California Diabetes Registry. J Gen Intern Med. 2008;23(3):275–282. doi: 10.1007/s11606-007-0502-zAhmed AT, Karter AJ, Warton EM, Doan JU, Weisner CM. The relationship between alcohol consumption and glycemic control among patients with diabetes: the Kaiser Permanente Northern California Diabetes Registry. J Gen Intern Med. 2008;23(3):275–282. doi: 10.1007/s11606-007-0502-zPietraszek A, Gregersen S, Hermansen K. Alcohol and type 2 diabetes. A review. Nutr Metab Cardiovasc Dis. 2010;20(5):366–375. doi: 10.1016/j.numecd.2010.05.001Pietraszek A, Gregersen S, Hermansen K. Alcohol and type 2 diabetes. A review. Nutr Metab Cardiovasc Dis. 2010;20(5):366–375. doi: 10.1016/j.numecd.2010.05.001Physical Activity Guidelines Advisory Committee. 2018 Physical Activity Guidelines Advisory Committee Scientific Report. Washington; 2018;Physical Activity Guidelines Advisory Committee. 2018 Physical Activity Guidelines Advisory Committee Scientific Report. Washington; 2018;Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218–1227. doi: 10.1001/jama.286.10.1218Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218–1227. doi: 10.1001/jama.286.10.1218Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, Gregg EW, et al. Lifestyle Change and Mobility in Obese Adults with Type 2 Diabetes. N Engl J Med. 2012;366(13):1209–1217. doi: 10.1056/NEJMoa1110294Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, Gregg EW, et al. Lifestyle Change and Mobility in Obese Adults with Type 2 Diabetes. N Engl J Med. 2012;366(13):1209–1217. doi: 10.1056/NEJMoa1110294Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and Type 2 Diabetes: The American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care. 2010;33(12):2692–2696. doi: 10.2337/dc10-1548Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and Type 2 Diabetes: The American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care. 2010;33(12):2692–2696. doi: 10.2337/dc10-1548Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of Aerobic and Resistance Training on Hemoglobin A 1c Levels in Patients With Type 2 Diabetes. JAMA. 2010;304(20):2253–2262. doi: 10.1001/jama.2010.1710Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, et al. Effects of Aerobic and Resistance Training on Hemoglobin A 1c Levels in Patients With Type 2 Diabetes. JAMA. 2010;304(20):2253–2262. doi: 10.1001/jama.2010.1710Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, et al. Physical Activity and Mortality in Individuals With Diabetes Mellitus. Arch Intern Med. 2012;172(17):1285–1295. doi: 10.1001/archinternmed.2012.3130Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, et al. Physical Activity and Mortality in Individuals With Diabetes Mellitus. Arch Intern Med. 2012;172(17):1285–1295. doi: 10.1001/archinternmed.2012.3130Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–2079. doi: 10.2337/dc16-1728Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–2079. doi: 10.2337/dc16-1728Jelleyman C, Yates T, O’Donovan G, Gray LJ, King JA, Khunti K, et al. The effects of high-intensity interval training on glucose regulation and insulin resistance: a meta-analysis. Obes Rev. 2015;16(11):942–961. doi: 10.1111/obr.12317Jelleyman C, Yates T, O’Donovan G, Gray LJ, King JA, Khunti K, et al. The effects of high-intensity interval training on glucose regulation and insulin resistance: a meta-analysis. Obes Rev. 2015;16(11):942–961. doi: 10.1111/obr.12317Little JP, Gillen JB, Percival ME, Safdar A, Tarnopolsky MA, Punthakee Z, et al. Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. J Appl Physiol. 2011;111(6):1554–1560. doi: 10.1152/japplphysiol.00921.2011Little JP, Gillen JB, Percival ME, Safdar A, Tarnopolsky MA, Punthakee Z, et al. Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. J Appl Physiol. 2011;111(6):1554–1560. doi: 10.1152/japplphysiol.00921.2011U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. 2008;U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans. 2008;Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Ann Intern Med. 2016;164(11):740–751. doi: 10.7326/M15-2650Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Ann Intern Med. 2016;164(11):740–751. doi: 10.7326/M15-2650Federation ID. IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care. Brussels: International Diabetes Federation; 2017; 34 p.Federation ID. IDF Clinical Practice Recommendations for managing Type 2 Diabetes in Primary Care. Brussels: International Diabetes Federation; 2017; 34 p.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;:pii: S0140-6736(19)31149-3 [Epub ahead of print]. doi: 10.1016/S0140-6736(19)31149-3Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;:pii: S0140-6736(19)31149-3 [Epub ahead of print]. doi: 10.1016/S0140-6736(19)31149-3Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. doi: 10.1016/S0140-6736(18)32590-XZelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. doi: 10.1016/S0140-6736(18)32590-XBethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–113. doi: 10.1016/S2213-8587(17)30412-6Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–113. doi: 10.1016/S2213-8587(17)30412-6Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139(17):2022–2031. doi: 10.1161/CIRCULATIONAHA.118.038868Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139(17):2022–2031. doi: 10.1161/CIRCULATIONAHA.118.038868Singh AK, Singh R. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Rev Clin Pharmacol. 2019;12(4):299–308. doi: 10.1080/17512433.2019.1588110Singh AK, Singh R. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Rev Clin Pharmacol. 2019;12(4):299–308. doi: 10.1080/17512433.2019.1588110Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018;137(2):119–129. doi: 10.1161/CIRCULATIONAHA.117.028268Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018;137(2):119–129. doi: 10.1161/CIRCULATIONAHA.117.028268Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839–848. doi: 10.1056/NEJMoa1616011Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(9):839–848. doi: 10.1056/NEJMoa1616011Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–138. doi: 10.1016/S0140-6736(19)31150-XGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–138. doi: 10.1016/S0140-6736(19)31150-XErpeldinger S, Rehman MB, Berkhout C, Pigache C, Zerbib Y, Regnault F, et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord. 2016;16(1):39. doi: 10.1186/s12902-016-0120-zErpeldinger S, Rehman MB, Berkhout C, Pigache C, Zerbib Y, Regnault F, et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord. 2016;16(1):39. doi: 10.1186/s12902-016-0120-zOwens DR, Traylor L, Mullins P, Landgraf W. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract. 2017;124:57–65. doi: 10.1016/j.diabres.2016.10.022Owens DR, Traylor L, Mullins P, Landgraf W. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract. 2017;124:57–65. doi: 10.1016/j.diabres.2016.10.022Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров АЮ, et al. Инициация и интенсификация сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015). Сахарный диабет. 2015;18(1):5–23. doi: 10.14341/DM201515-23Дедов ИИ, Шестакова МВ, Аметов АС, Анциферов МБ, Галстян ГР, Майоров АЮ, et al. Инициация и интенсификация сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015). Сахарный диабет. 2015;18(1):5–23. doi: 10.14341/DM201515-23Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–265. doi: 10.2337/diacare.28.2.260Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–265. doi: 10.2337/diacare.28.2.260Porcellati F, Lucidi P, Cioli P, Candeloro P, Marinelli Andreoli A, Marzotti S, et al. Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes. Diabetes Care. 2015;38(3):503–512. doi: 10.2337/dc14-0649Porcellati F, Lucidi P, Cioli P, Candeloro P, Marinelli Andreoli A, Marzotti S, et al. Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes. Diabetes Care. 2015;38(3):503–512. doi: 10.2337/dc14-0649Wang Z, Hedrington MS, Gogitidze Joy N, Briscoe VJ, Richardson MA, Younk L, et al. Dose-Response Effects of Insulin Glargine in Type 2 Diabetes. Diabetes Care. 2010;33(7):1555–1560. doi: 10.2337/dc09-2011Wang Z, Hedrington MS, Gogitidze Joy N, Briscoe VJ, Richardson MA, Younk L, et al. Dose-Response Effects of Insulin Glargine in Type 2 Diabetes. Diabetes Care. 2010;33(7):1555–1560. doi: 10.2337/dc09-2011Cai X, Gao X, Yang W, Ji L. Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Expert Opin Pharmacother. 2017;18(17):1789–1798. doi: 10.1080/14656566.2017.1400011Cai X, Gao X, Yang W, Ji L. Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Expert Opin Pharmacother. 2017;18(17):1789–1798. doi: 10.1080/14656566.2017.1400011Gough SCL, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 di. Lancet Diabetes Endocrinol. 2014;2(11):885–893. doi: 10.1016/S2213-8587(14)70174-3Gough SCL, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 di. Lancet Diabetes Endocrinol. 2014;2(11):885–893. doi: 10.1016/S2213-8587(14)70174-3Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care. 2016;39(11):2026–2035. doi: 10.2337/dc16-0917Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care. 2016;39(11):2026–2035. doi: 10.2337/dc16-0917Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. Can Med Assoc J. 2009;180(4):385–397. doi: 10.1503/cmaj.081041Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. Can Med Assoc J. 2009;180(4):385–397. doi: 10.1503/cmaj.081041Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane database Syst Rev. 2007;(2):CD005613. doi: 10.1002/14651858.CD005613.pub3Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane database Syst Rev. 2007;(2):CD005613. doi: 10.1002/14651858.CD005613.pub3Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):184–189. doi: 10.1016/j.diabres.2008.04.007Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):184–189. doi: 10.1016/j.diabres.2008.04.007Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086. doi: 10.2337/diacare.26.11.3080Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086. doi: 10.2337/diacare.26.11.3080Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care. 2006;29(6):1269–1274. doi: 10.2337/dc05-1365Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care. 2006;29(6):1269–1274. doi: 10.2337/dc05-1365Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes, Obes Metab. 2015;17(4):386–394. doi: 10.1111/dom.12438Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes, Obes Metab. 2015;17(4):386–394. doi: 10.1111/dom.12438Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes, Obes Metab. 2016;18(4):366–374. doi: 10.1111/dom.12618Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes, Obes Metab. 2016;18(4):366–374. doi: 10.1111/dom.12618Yki-Järvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensi. Diabetes, Obes Metab. 2015;17(12):1142–1149. doi: 10.1111/dom.12532Yki-Järvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensi. Diabetes, Obes Metab. 2015;17(12):1142–1149. doi: 10.1111/dom.12532Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723–732. doi: 10.1056/NEJMoa1615692Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723–732. doi: 10.1056/NEJMoa1615692Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth T V., et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013;30(11):1298–1304. doi: 10.1111/dme.12303Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth T V., et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013;30(11):1298–1304. doi: 10.1111/dme.12303Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes. JAMA. 2017;318(1):45–56. doi: 10.1001/jama.2017.7117Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes. JAMA. 2017;318(1):45–56. doi: 10.1001/jama.2017.7117Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–2471. doi: 10.2337/dc12-1205Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–2471. doi: 10.2337/dc12-1205Madenidou A-V, Paschos P, Karagiannis T, Katsoula A, Athanasiadou E, Kitsios K, et al. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. Ann Intern Med. 2018;169(3):165–174. doi: 10.7326/M18-0443Madenidou A-V, Paschos P, Karagiannis T, Katsoula A, Athanasiadou E, Kitsios K, et al. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. Ann Intern Med. 2018;169(3):165–174. doi: 10.7326/M18-0443Roussel R, Ritzel R, Boëlle-Le Corfec E, Balkau B, Rosenstock J. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM. Diabetes Metab. 2018;44(5):402–409. doi: 10.1016/j.diabet.2018.02.002Roussel R, Ritzel R, Boëlle-Le Corfec E, Balkau B, Rosenstock J. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM. Diabetes Metab. 2018;44(5):402–409. doi: 10.1016/j.diabet.2018.02.002Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis. Clin Ther. 2009;31(8):1641–1651. doi: 10.1016/j.clinthera.2009.08.011Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis. Clin Ther. 2009;31(8):1641–1651. doi: 10.1016/j.clinthera.2009.08.011Rys P, Wojciechowski P, Siejka S, Małecki P, Hak Ł, Malecki MT. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus - a systematic review and meta-analysis. Int J Clin Pract. 2014;68(3):304–313. doi: 10.1111/ijcp.12337Rys P, Wojciechowski P, Siejka S, Małecki P, Hak Ł, Malecki MT. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus - a systematic review and meta-analysis. Int J Clin Pract. 2014;68(3):304–313. doi: 10.1111/ijcp.12337Riddle MC, Yki-Järvinen H, Bolli GB, Ziemen M, Muehlen-Bartmer I, Cissokho S, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes, Obes Metab. 2015;17(9):835–842. doi: 10.1111/dom.12472Riddle MC, Yki-Järvinen H, Bolli GB, Ziemen M, Muehlen-Bartmer I, Cissokho S, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes, Obes Metab. 2015;17(9):835–842. doi: 10.1111/dom.12472Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes. 2013;5(4):482–491. doi: 10.1111/1753-0407.12060Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes. 2013;5(4):482–491. doi: 10.1111/1753-0407.12060Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes, Obes Metab. 2009;11(1):53–59. doi: 10.1111/j.1463-1326.2008.00934.xMannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes, Obes Metab. 2009;11(1):53–59. doi: 10.1111/j.1463-1326.2008.00934.xRodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014;2(1):30–37. doi: 10.1016/S2213-8587(13)70090-1Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014;2(1):30–37. doi: 10.1016/S2213-8587(13)70090-1Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, et al. Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diabetes Care. 2014;37(10):2763–2773. doi: 10.2337/dc14-0876Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, et al. Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diabetes Care. 2014;37(10):2763–2773. doi: 10.2337/dc14-0876Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228–2234. doi: 10.1016/S0140-6736(14)61335-0Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228–2234. doi: 10.1016/S0140-6736(14)61335-0Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2017;40(4):614–624. doi: 10.2337/dc16-1957Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2017;40(4):614–624. doi: 10.2337/dc16-1957Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, et al. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926–2933. doi: 10.2337/dc14-0785Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, et al. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926–2933. doi: 10.2337/dc14-0785Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, González-Gálvez G, et al. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care. 2016;39(11):1972–1980. doi: 10.2337/dc16-1495Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, González-Gálvez G, et al. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care. 2016;39(11):1972–1980. doi: 10.2337/dc16-1495Triplitt C. How to Initiate, Titrate, and Intensify Insulin Treatment in Type 2 Diabetes. US Pharm [Internet]. 2017;32(10):10–16.Triplitt C. How to Initiate, Titrate, and Intensify Insulin Treatment in Type 2 Diabetes. US Pharm [Internet]. 2017;32(10):10–16.Elliott J, Lawton J, Rankin D, Emery C, Campbell M, Dixon S, et al. The 5x1 DAFNE study protocol: a cluster randomised trial comparing a standard 5 day DAFNE course delivered over 1 week against DAFNE training delivered over 1 day a week for 5 consecutive weeks. BMC Endocr Disord. 2012;12(1):28. doi: 10.1186/1472-6823-12-28Elliott J, Lawton J, Rankin D, Emery C, Campbell M, Dixon S, et al. The 5x1 DAFNE study protocol: a cluster randomised trial comparing a standard 5 day DAFNE course delivered over 1 week against DAFNE training delivered over 1 day a week for 5 consecutive weeks. BMC Endocr Disord. 2012;12(1):28. doi: 10.1186/1472-6823-12-28Haas L, Maryniuk M, Beck J, Cox CE, Duker P, Edwards L, et al. National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2013;36(Supplement_1):S100–S108. doi: 10.2337/dc13-S100Haas L, Maryniuk M, Beck J, Cox CE, Duker P, Edwards L, et al. National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2013;36(Supplement_1):S100–S108. doi: 10.2337/dc13-S100Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Hess Fischl A, et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015;38(7):1372–1382. doi: 10.2337/dc15-0730Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Hess Fischl A, et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015;38(7):1372–1382. doi: 10.2337/dc15-0730Майоров АЮ, Мельникова ОГ, Котешкова ОМ, Мисникова ИВ, Черникова НА. Техника инъекций и инфузии при лечении сахарного диабета. Методическое руководство. Москва: ООО “АРТИНФО”; 2018; 64 p.Майоров АЮ, Мельникова ОГ, Котешкова ОМ, Мисникова ИВ, Черникова НА. Техника инъекций и инфузии при лечении сахарного диабета. Методическое руководство. Москва: ООО “АРТИНФО”; 2018; 64 p.Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016;91(9):1231–1255. doi: 10.1016/j.mayocp.2016.06.010Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016;91(9):1231–1255. doi: 10.1016/j.mayocp.2016.06.010Uzun S, Inanc N, Azal S. Determining optimal needle length for subcutaneous insulin injection. J Diab Nurs [Internet]. 2001;5(10):83–87.Uzun S, Inanc N, Azal S. Determining optimal needle length for subcutaneous insulin injection. J Diab Nurs [Internet]. 2001;5(10):83–87.Hirsch LJ, Gibney MA, Albanese J, Qu S, Kassler-Taub K, Klaff LJ, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26(6):1531–1541. doi: 10.1185/03007995.2010.482499Hirsch LJ, Gibney MA, Albanese J, Qu S, Kassler-Taub K, Klaff LJ, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26(6):1531–1541. doi: 10.1185/03007995.2010.482499Miwa T, Itoh R, Kobayashi T, Tanabe T, Shikuma J, Takahashi T, et al. Comparison of the Effects of a New 32-Gauge×4-mm Pen Needle and a 32-Gauge×6-mm Pen Needle on Glycemic Control, Safety, and Patient Ratings in Japanese Adults with Diabetes. Diabetes Technol Ther. 2012;14(12):1084–1090. doi: 10.1089/dia.2012.0170Miwa T, Itoh R, Kobayashi T, Tanabe T, Shikuma J, Takahashi T, et al. Comparison of the Effects of a New 32-Gauge×4-mm Pen Needle and a 32-Gauge×6-mm Pen Needle on Glycemic Control, Safety, and Patient Ratings in Japanese Adults with Diabetes. Diabetes Technol Ther. 2012;14(12):1084–1090. doi: 10.1089/dia.2012.0170Nagai Y, Ohshige T, Arai K, Kobayashi H, Sada Y, Ohmori S, et al. Comparison Between Shorter Straight and Thinner Microtapered Insulin Injection Needles. Diabetes Technol Ther. 2013;15(7):550–555. doi: 10.1089/dia.2012.0334Nagai Y, Ohshige T, Arai K, Kobayashi H, Sada Y, Ohmori S, et al. Comparison Between Shorter Straight and Thinner Microtapered Insulin Injection Needles. Diabetes Technol Ther. 2013;15(7):550–555. doi: 10.1089/dia.2012.0334Bergenstal RM, Strock ES, Peremislov D, Gibney MA, Parvu V, Hirsch LJ. Safety and Efficacy of Insulin Therapy Delivered via a 4mm Pen Needle in Obese Patients With Diabetes. Mayo Clin Proc. 2015;90(3):329–338. doi: 10.1016/j.mayocp.2014.12.014Bergenstal RM, Strock ES, Peremislov D, Gibney MA, Parvu V, Hirsch LJ. Safety and Efficacy of Insulin Therapy Delivered via a 4mm Pen Needle in Obese Patients With Diabetes. Mayo Clin Proc. 2015;90(3):329–338. doi: 10.1016/j.mayocp.2014.12.014Kreugel G, Kees J, Jongbloed A, Verweij-Gjaltema A, Wolffenbuttel B. The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes [Internet]. 2009;58:A117.Kreugel G, Kees J, Jongbloed A, Verweij-Gjaltema A, Wolffenbuttel B. The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes [Internet]. 2009;58:A117.Schwartz S, Hassman D, Shelmet J, Sievers R, Weinstein R, Liang J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26(10):1663–1678. doi: 10.1016/j.clinthera.2004.10.007Schwartz S, Hassman D, Shelmet J, Sievers R, Weinstein R, Liang J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26(10):1663–1678. doi: 10.1016/j.clinthera.2004.10.007Strauss K, Hannet I, McGonigle J, Parkes J, Ginsberg B, Jamal R, et al. Ultra-short (5 mm) insulin needles: Trial results and clinical recommendations. Pract Diabetes Int. 1999;16(7):218–222. doi: 10.1002/pdi.1960160711Strauss K, Hannet I, McGonigle J, Parkes J, Ginsberg B, Jamal R, et al. Ultra-short (5 mm) insulin needles: Trial results and clinical recommendations. Pract Diabetes Int. 1999;16(7):218–222. doi: 10.1002/pdi.1960160711Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BHR. Randomized Trial on the Influence of the Length of Two Insulin Pen Needles on Glycemic Control and Patient Preference in Obese Patients with Diabetes. Diabetes Technol Ther. 2011;13(7):737–741. doi: 10.1089/dia.2011.0010Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BHR. Randomized Trial on the Influence of the Length of Two Insulin Pen Needles on Glycemic Control and Patient Preference in Obese Patients with Diabetes. Diabetes Technol Ther. 2011;13(7):737–741. doi: 10.1089/dia.2011.0010McKay M, Compion G, Lytzen L. A Comparison of Insulin Injection Needles on Patients’ Perceptions of Pain, Handling, and Acceptability: A Randomized, Open-Label, Crossover Study in Subjects with Diabetes. Diabetes Technol Ther. 2009;11(3):195–201. doi: 10.1089/dia.2008.0054McKay M, Compion G, Lytzen L. A Comparison of Insulin Injection Needles on Patients’ Perceptions of Pain, Handling, and Acceptability: A Randomized, Open-Label, Crossover Study in Subjects with Diabetes. Diabetes Technol Ther. 2009;11(3):195–201. doi: 10.1089/dia.2008.0054Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm Needle Reduces the Risk of Intramuscular Injections Without Increasing Backflow to Skin Surface in Lean Diabetic Children and Adults. Diabetes Care. 2008;31(9):e65. doi: 10.2337/dc08-0977Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm Needle Reduces the Risk of Intramuscular Injections Without Increasing Backflow to Skin Surface in Lean Diabetic Children and Adults. Diabetes Care. 2008;31(9):e65. doi: 10.2337/dc08-0977Schuler G, Pelz K, Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diabetes Res Clin Pract. 1992;16(3):209–212.Schuler G, Pelz K, Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diabetes Res Clin Pract. 1992;16(3):209–212.Johansson U-B, Amsberg S, Hannerz L, Wredling R, Adamson U, Arnqvist HJ, et al. Impaired Absorption of Insulin Aspart From Lipohypertrophic Injection Sites. Diabetes Care. 2005;28(8):2025–2027. doi: 10.2337/diacare.28.8.2025Johansson U-B, Amsberg S, Hannerz L, Wredling R, Adamson U, Arnqvist HJ, et al. Impaired Absorption of Insulin Aspart From Lipohypertrophic Injection Sites. Diabetes Care. 2005;28(8):2025–2027. doi: 10.2337/diacare.28.8.2025Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003;327(7411):383–384. doi: 10.1136/bmj.327.7411.383Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003;327(7411):383–384. doi: 10.1136/bmj.327.7411.383Chantelau E, Lee DM, Hemmann DM, Zipfel U, Echterhoff S. What makes insulin injections painful? BMJ. 1991;303(6793):26–27. doi: 10.1136/bmj.303.6793.26Chantelau E, Lee DM, Hemmann DM, Zipfel U, Echterhoff S. What makes insulin injections painful? BMJ. 1991;303(6793):26–27. doi: 10.1136/bmj.303.6793.26Caffrey R. Are All Syringes Created Equal?: How to choose and use today’s insulin syringes. Am J Nurs [Internet]. 2003;103(6):46–49.Caffrey R. Are All Syringes Created Equal?: How to choose and use today’s insulin syringes. Am J Nurs [Internet]. 2003;103(6):46–49.Braak EWT, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JHH, et al. Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin. Diabetes Care. 1996;19(12):1437–1440. doi: 10.2337/diacare.19.12.1437Braak EWT, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JHH, et al. Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin. Diabetes Care. 1996;19(12):1437–1440. doi: 10.2337/diacare.19.12.1437Frid A. Fat thickness and insulin administration, what do we know? Infusystems Int [Internet]. 2006;5(3):17–19.Frid A. Fat thickness and insulin administration, what do we know? Infusystems Int [Internet]. 2006;5(3):17–19.Lippert WC, Wall EJ. Optimal Intramuscular Needle-Penetration Depth. Pediatrics. 2008;122(3):e556–e563. doi: 10.1542/peds.2008-0374Lippert WC, Wall EJ. Optimal Intramuscular Needle-Penetration Depth. Pediatrics. 2008;122(3):e556–e563. doi: 10.1542/peds.2008-0374Sonoki K, Yoshinari M, Iwase M, Tashiro K, Iino K, Wakisaka M, et al. Regurgitation of Blood into Insulin Cartridges in the Pen-like Injectors. Diabetes Care. 2001;24(3):603–604. doi: 10.2337/diacare.24.3.603Sonoki K, Yoshinari M, Iwase M, Tashiro K, Iino K, Wakisaka M, et al. Regurgitation of Blood into Insulin Cartridges in the Pen-like Injectors. Diabetes Care. 2001;24(3):603–604. doi: 10.2337/diacare.24.3.603Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, et al. Hepatitis B e Antigen and Infectivity of Hepatitis B Virus. J Infect Dis. 1977;136(4):571–576. doi: 10.1093/infdis/136.4.571Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, et al. Hepatitis B e Antigen and Infectivity of Hepatitis B Virus. J Infect Dis. 1977;136(4):571–576. doi: 10.1093/infdis/136.4.571Scioli D, Pizzella T, Vollaro L, Nardiello S, De Feo L. The action of VIRKON No Foam on the hepatitis B virus. Eur J Epidemiol. 1997;13(8):879–883. doi: 10.1023/A:1007399926095Scioli D, Pizzella T, Vollaro L, Nardiello S, De Feo L. The action of VIRKON No Foam on the hepatitis B virus. Eur J Epidemiol. 1997;13(8):879–883. doi: 10.1023/A:1007399926095Herdman ML, Larck C, Schliesser SH, Jelic TM. Biological contamination of insulin pens in a hospital setting. Am J Heal Pharm. 2013;70(14):1244–1248. doi: 10.2146/ajhp120728Herdman ML, Larck C, Schliesser SH, Jelic TM. Biological contamination of insulin pens in a hospital setting. Am J Heal Pharm. 2013;70(14):1244–1248. doi: 10.2146/ajhp120728Cochran J, Conn VS. Meta-analysis of Quality of Life Outcomes Following Diabetes Self-management Training. Diabetes Educ. 2008;34(5):815–823. doi: 10.1177/0145721708323640Cochran J, Conn VS. Meta-analysis of Quality of Life Outcomes Following Diabetes Self-management Training. Diabetes Educ. 2008;34(5):815–823. doi: 10.1177/0145721708323640Foster G, Taylor SJC, Eldridge SE, Ramsay J, Griffiths CJ. Self-management education programmes by lay leaders for people with chronic conditions. Cochrane database Syst Rev. 2007;(4):CD005108. doi: 10.1002/14651858.CD005108.pub2Foster G, Taylor SJC, Eldridge SE, Ramsay J, Griffiths CJ. Self-management education programmes by lay leaders for people with chronic conditions. Cochrane database Syst Rev. 2007;(4):CD005108. doi: 10.1002/14651858.CD005108.pub2Johnson TM, Murray MR, Huang Y. Associations Between Self-Management Education and Comprehensive Diabetes Clinical Care. Diabetes Spectr. 2010;23(1):41–46. doi: 10.2337/diaspect.23.1.41Johnson TM, Murray MR, Huang Y. Associations Between Self-Management Education and Comprehensive Diabetes Clinical Care. Diabetes Spectr. 2010;23(1):41–46. doi: 10.2337/diaspect.23.1.41Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KGMM, Zimmet PZ, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861–877. doi: 10.2337/dc16-0236Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KGMM, Zimmet PZ, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861–877. doi: 10.2337/dc16-0236Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018;61(2):257–264. doi: 10.1007/s00125-017-4513-yCummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018;61(2):257–264. doi: 10.1007/s00125-017-4513-yДедов ИИ, Мельниченко ГА, Шестакова МВ, Трошина ЕА, Мазурина НВ, Шестакова ЕА, et al. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр (лечение морбидного ожирения у взрослых). Ожирение и метаболизм [Internet]. 2018;15(1):53–70. doi: 10.14341/OMET2018153-70Дедов ИИ, Мельниченко ГА, Шестакова МВ, Трошина ЕА, Мазурина НВ, Шестакова ЕА, et al. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр (лечение морбидного ожирения у взрослых). Ожирение и метаболизм [Internet]. 2018;15(1):53–70. doi: 10.14341/OMET2018153-70Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. Am J Med. 2009;122(3):248-256.e5. doi: 10.1016/j.amjmed.2008.09.041Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. Am J Med. 2009;122(3):248-256.e5. doi: 10.1016/j.amjmed.2008.09.041Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: Cosponsored by american association of clinical endocrinologists, The obesity society, and american society fo. Obesity. 2013;21(S1):S1–S27. doi: 10.1002/oby.20461Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: Cosponsored by american association of clinical endocrinologists, The obesity society, and american society fo. Obesity. 2013;21(S1):S1–S27. doi: 10.1002/oby.20461Busetto L, Dicker D, Azran C, Batterham RL, Farpour-Lambert N, Fried M, et al. Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. Obes Facts. 2017;10(6):597–632. doi: 10.1159/000481825Busetto L, Dicker D, Azran C, Batterham RL, Farpour-Lambert N, Fried M, et al. Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management. Obes Facts. 2017;10(6):597–632. doi: 10.1159/000481825Beck J, Greenwood DA, Blanton L, Bollinger ST, Butcher MK, Condon JE, et al. 2017 National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2017;40(10):1409–1419. doi: 10.2337/dci17-0025Beck J, Greenwood DA, Blanton L, Bollinger ST, Butcher MK, Condon JE, et al. 2017 National Standards for Diabetes Self-Management Education and Support. Diabetes Care. 2017;40(10):1409–1419. doi: 10.2337/dci17-0025Muhlhauser I, Berger M. Patient education - evaluation of a complex intervention. Diabetologia. 2002;45(12):1723–1733. doi: 10.1007/s00125-002-0987-2Muhlhauser I, Berger M. Patient education - evaluation of a complex intervention. Diabetologia. 2002;45(12):1723–1733. doi: 10.1007/s00125-002-0987-2Майоров АЮ, Суркова ЕВ, Мотовилин ОГ, Мельникова ОГ, Шишкова ЮА. Обучение больных диабетом: синтез доказательной медицины и психологического подхода. Сахарный диабет [Internet]. 2011;14(1):46–52. doi: 10.14341/2072-0351-6249Майоров АЮ, Суркова ЕВ, Мотовилин ОГ, Мельникова ОГ, Шишкова ЮА. Обучение больных диабетом: синтез доказательной медицины и психологического подхода. Сахарный диабет [Internet]. 2011;14(1):46–52. doi: 10.14341/2072-0351-6249Deakin T, Whitham C. Structured patient education: the X-PERT Programme. Br J Community Nurs. 2009;14(9):398–404. doi: 10.12968/bjcn.2009.14.9.43916Deakin T, Whitham C. Structured patient education: the X-PERT Programme. Br J Community Nurs. 2009;14(9):398–404. doi: 10.12968/bjcn.2009.14.9.43916Clark M. Diabetes self-management education: A review of published studies. Prim Care Diabetes. 2008;2(3):113–120. doi: 10.1016/j.pcd.2008.04.004Clark M. Diabetes self-management education: A review of published studies. Prim Care Diabetes. 2008;2(3):113–120. doi: 10.1016/j.pcd.2008.04.004Steinsbekk A, Rygg L, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res. 2012;12(1):213. doi: 10.1186/1472-6963-12-213Steinsbekk A, Rygg L, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res. 2012;12(1):213. doi: 10.1186/1472-6963-12-213Deakin T, McShane CE, Cade JE, Williams RDRR. Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane database Syst Rev. 2005;(2):CD003417. doi: 10.1002/14651858.CD003417.pub2Deakin T, McShane CE, Cade JE, Williams RDRR. Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane database Syst Rev. 2005;(2):CD003417. doi: 10.1002/14651858.CD003417.pub2Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25(7):1159–1171. doi: 10.2337/diacare.25.7.1159Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25(7):1159–1171. doi: 10.2337/diacare.25.7.1159He X, Li J, Wang B, Yao Q, Li L, Song R, et al. Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine. 2017;55(3):712–731. doi: 10.1007/s12020-016-1168-2He X, Li J, Wang B, Yao Q, Li L, Song R, et al. Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine. 2017;55(3):712–731. doi: 10.1007/s12020-016-1168-2Assal JP. Educating the diabetic patient: which programme is specific to IDDM and to NIDDM? In: de Gryter W, editor. Concepts for the ideal diabetes clinic [Internet]. New Yourk; 1992; p. 89–104.Assal JP. Educating the diabetic patient: which programme is specific to IDDM and to NIDDM? In: de Gryter W, editor. Concepts for the ideal diabetes clinic [Internet]. New Yourk; 1992; p. 89–104.Анциферов МБ, Майоров АЮ, Суркова ЕВ, Мартынов ВЛ. Пособие для врачей «Структурированные программы обучения больных сахарным диабетом». Дедов ИИ, editor. 2003;Анциферов МБ, Майоров АЮ, Суркова ЕВ, Мартынов ВЛ. Пособие для врачей «Структурированные программы обучения больных сахарным диабетом». Дедов ИИ, editor. 2003;Майоров АЮ, Суркова ЕВ, Галстян ГР, Токмакова АЮ. Структурированная программа обучения больных сахарным диабетом 2 типа на инсулинотерапии (с набором плакатов и карточек продуктов). 2006;Майоров АЮ, Суркова ЕВ, Галстян ГР, Токмакова АЮ. Структурированная программа обучения больных сахарным диабетом 2 типа на инсулинотерапии (с набором плакатов и карточек продуктов). 2006;Мельниченко ГА, Суркова ЕВ, Майоров АЮ, Галстян ГР, Токмакова АЮ, Дедов ИИ. Результаты применения структурированной программы обучения больных сахарным диабетом 2 типа на инсулинотерапии. Сахарный диабет [Internet]. 2008;11(4):71–75. doi: 10.14341/2072-0351-5595Мельниченко ГА, Суркова ЕВ, Майоров АЮ, Галстян ГР, Токмакова АЮ, Дедов ИИ. Результаты применения структурированной программы обучения больных сахарным диабетом 2 типа на инсулинотерапии. Сахарный диабет [Internet]. 2008;11(4):71–75. doi: 10.14341/2072-0351-5595Duncan I, Ahmed T, Li Q (Emily), Stetson B, Ruggiero L, Burton K, et al. Assessing the Value of the Diabetes Educator. Diabetes Educ. 2011;37(5):638–657. doi: 10.1177/0145721711416256Duncan I, Ahmed T, Li Q (Emily), Stetson B, Ruggiero L, Burton K, et al. Assessing the Value of the Diabetes Educator. Diabetes Educ. 2011;37(5):638–657. doi: 10.1177/0145721711416256DESG Working Group. Basic Curriculum for Health Сare Professionals on Diabetes Therapeutic Education. 2001;DESG Working Group. Basic Curriculum for Health Сare Professionals on Diabetes Therapeutic Education. 2001;Дедов ИИ, Суркова ЕВ, Майоров АЮ, Галстян ГР, Анциферов МБ, Токмакова АЮ. Программа подготовки специалистов в области обучения больных сахарным диабетом. Сахарный диабет [Internet]. 2003;6(1):44–47. doi: 10.14341/2072-0351-6045Дедов ИИ, Суркова ЕВ, Майоров АЮ, Галстян ГР, Анциферов МБ, Токмакова АЮ. Программа подготовки специалистов в области обучения больных сахарным диабетом. Сахарный диабет [Internet]. 2003;6(1):44–47. doi: 10.14341/2072-0351-6045Дедов ИИ, Суркова ЕВ, Майоров АЮ, Галстян ГР, Токмакова АЮ. Терапевтическое обучение больных сахарным диабетом. Москва: Реафарм; 2004; 200 с.Дедов ИИ, Суркова ЕВ, Майоров АЮ, Галстян ГР, Токмакова АЮ. Терапевтическое обучение больных сахарным диабетом. Москва: Реафарм; 2004; 200 с.Суркова ЕВ, Майоров АЮ, Галстян ГР, Токмакова АЮ. Обучение больных сахарным диабетом: Руководство для эндокринологов. Дедов ИИ, editor. Москва: Медицина для Вас; 2007.Суркова ЕВ, Майоров АЮ, Галстян ГР, Токмакова АЮ. Обучение больных сахарным диабетом: Руководство для эндокринологов. Дедов ИИ, editor. Москва: Медицина для Вас; 2007.Всемирная Организация Здравоохранения. Терапевтическое обучение больных. Программы непрерывного обучения для работников здравоохранения в области профилактики хронических заболеваний. Отчет рабочей группы ВОЗ. Москва; 1998;Всемирная Организация Здравоохранения. Терапевтическое обучение больных. Программы непрерывного обучения для работников здравоохранения в области профилактики хронических заболеваний. Отчет рабочей группы ВОЗ. Москва; 1998;Sadosky A, Schaefer C, Mann R, Bergstrom F, Baik R, Parsons B, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes. 2013;6:79–92. doi: 10.2147/DMSO.S37415Sadosky A, Schaefer C, Mann R, Bergstrom F, Baik R, Parsons B, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes. 2013;6:79–92. doi: 10.2147/DMSO.S37415Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi: 10.1016/S1474-4422(14)70251-0Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi: 10.1016/S1474-4422(14)70251-0Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tölle T, Bouhassira D, et al. Duloxetine and pregabalin: High-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–2625. doi: 10.1016/j.pain.2013.05.043Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tölle T, Bouhassira D, et al. Duloxetine and pregabalin: High-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–2625. doi: 10.1016/j.pain.2013.05.043Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life. Neurology. 2017;88(20):1958–1967. doi: 10.1212/WNL.0000000000003882Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life. Neurology. 2017;88(20):1958–1967. doi: 10.1212/WNL.0000000000003882Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938. doi: 10.1002/14651858.CD007938.pub4Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938. doi: 10.1002/14651858.CD007938.pub4Wernicke JF, Pritchett YL, D’Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411–1420. doi: 10.1212/01.wnl.0000240225.04000.1aWernicke JF, Pritchett YL, D’Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411–1420. doi: 10.1212/01.wnl.0000240225.04000.1aSchwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151–162. doi: 10.1185/03007995.2010.537589Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151–162. doi: 10.1185/03007995.2010.537589Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013;36(5):1384–1395. doi: 10.2337/dc12-2480Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013;36(5):1384–1395. doi: 10.2337/dc12-2480Cryer PE. Diverse Causes of Hypoglycemia-Associated Autonomic Failure in Diabetes. N Engl J Med. 2004;350(22):2272–2279. doi: 10.1056/NEJMra031354Cryer PE. Diverse Causes of Hypoglycemia-Associated Autonomic Failure in Diabetes. N Engl J Med. 2004;350(22):2272–2279. doi: 10.1056/NEJMra031354Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. J Clin Endocrinol Metab. 2013;98(5):1845–1859. doi: 10.1210/jc.2012-4127Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. J Clin Endocrinol Metab. 2013;98(5):1845–1859. doi: 10.1210/jc.2012-4127Slama G, Traynard PY, Desplanque N, Pudar H, Dhunputh I, Letanoux M, et al. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solutin, or gel for the correction of insulin reactions. Arch Intern Med. 1990;150(3):589–593.Slama G, Traynard PY, Desplanque N, Pudar H, Dhunputh I, Letanoux M, et al. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solutin, or gel for the correction of insulin reactions. Arch Intern Med. 1990;150(3):589–593.Cryer PE, Preceded by: Cryer PE. Hypoglycemia in diabetes : pathophysiology, prevalence, and prevention [Internet]. American Diabetes Association; 2016; 254 p.Cryer PE, Preceded by: Cryer PE. Hypoglycemia in diabetes : pathophysiology, prevalence, and prevention [Internet]. American Diabetes Association; 2016; 254 p.Karter AJ, Moffet HH, Liu JY, Lipska KJ. Surveillance of Hypoglycemia—Limitations of Emergency Department and Hospital Utilization Data. JAMA Intern Med. 2018;178(7):987–988. doi: 10.1001/jamainternmed.2018.1014Karter AJ, Moffet HH, Liu JY, Lipska KJ. Surveillance of Hypoglycemia—Limitations of Emergency Department and Hospital Utilization Data. JAMA Intern Med. 2018;178(7):987–988. doi: 10.1001/jamainternmed.2018.1014Eli Lilly Canada Inc. Glucagon (rDNA Origin) Product Monograph. Toronto; 2012; 32 p.Eli Lilly Canada Inc. Glucagon (rDNA Origin) Product Monograph. Toronto; 2012; 32 p.Nordisk N. GlucaGen® (glucagon) Product monograph. Bagsvaerd; 2002;Nordisk N. GlucaGen® (glucagon) Product monograph. Bagsvaerd; 2002;Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med. 2001;344(18):1343–1350. doi: 10.1056/NEJM200105033441801Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med. 2001;344(18):1343–1350. doi: 10.1056/NEJM200105033441801Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. doi: 10.1056/NEJMoa012512Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. doi: 10.1056/NEJMoa012512Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (London, England). 2009;374(9702):1677–1686. doi: 10.1016/S0140-6736(09)61457-4Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (London, England). 2009;374(9702):1677–1686. doi: 10.1016/S0140-6736(09)61457-4Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. lancet Diabetes Endocrinol. 2015;3(11):866–875. doi: 10.1016/S2213-8587(15)00291-0Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. lancet Diabetes Endocrinol. 2015;3(11):866–875. doi: 10.1016/S2213-8587(15)00291-0Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Depe. Diabetes Care. 1998;21(10):1720–1725. doi: 10.2337/diacare.21.10.1720Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Depe. Diabetes Care. 1998;21(10):1720–1725. doi: 10.2337/diacare.21.10.1720International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009;32(7):1327–1334. doi: 10.2337/dc09-9033International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009;32(7):1327–1334. doi: 10.2337/dc09-9033Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, et al. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis. 2019;73(2):206–217. doi: 10.1053/j.ajkd.2018.08.013Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, et al. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis. 2019;73(2):206–217. doi: 10.1053/j.ajkd.2018.08.013James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis. 2015;66(4):602–612. doi: 10.1053/j.ajkd.2015.02.338James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis. 2015;66(4):602–612. doi: 10.1053/j.ajkd.2015.02.338Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee, Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, et al. Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary. Can J Ophthalmol. 2012;47(2):91–101. doi: 10.1016/j.jcjo.2012.01.022Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee, Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, et al. Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary. Can J Ophthalmol. 2012;47(2):91–101. doi: 10.1016/j.jcjo.2012.01.022Дедов ИИ, Шестакова МВ. Осложнения сахарного диабета: лечение и профилактика. Москва: МИА; 2017; 743 с.Дедов ИИ, Шестакова МВ. Осложнения сахарного диабета: лечение и профилактика. Москва: МИА; 2017; 743 с.Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883. doi: 10.2337/dc14-1296Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883. doi: 10.2337/dc14-1296Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (London, England). 2012;380(9854):1662–1673. doi: 10.1016/S0140-6736(12)61350-6Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (London, England). 2012;380(9854):1662–1673. doi: 10.1016/S0140-6736(12)61350-6Kramer HJ, Nguyen QD, Curhan G, Hsu C-Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273–3277. doi: 10.1001/jama.289.24.3273Kramer HJ, Nguyen QD, Curhan G, Hsu C-Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273–3277. doi: 10.1001/jama.289.24.3273Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31(6):954–961.Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31(6):954–961.He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane database Syst Rev. 2004;(3):CD004937. doi: 10.1002/14651858.CD004937He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane database Syst Rev. 2004;(3):CD004937. doi: 10.1002/14651858.CD004937Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, et al. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. JAMA. 2016;315(20):2200–2210. doi: 10.1001/jama.2016.4447Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, et al. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. JAMA. 2016;315(20):2200–2210. doi: 10.1001/jama.2016.4447Nilsson E, Gasparini A, Ärnlöv J, Xu H, Henriksson KM, Coresh J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277–284. doi: 10.1016/j.ijcard.2017.07.035Nilsson E, Gasparini A, Ärnlöv J, Xu H, Henriksson KM, Coresh J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277–284. doi: 10.1016/j.ijcard.2017.07.035Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. lancet Diabetes Endocrinol. 2017;5(6):431–437. doi: 10.1016/S2213-8587(17)30104-3Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. lancet Diabetes Endocrinol. 2017;5(6):431–437. doi: 10.1016/S2213-8587(17)30104-3Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. 2014;371(15):1392–1406. doi: 10.1056/NEJMoa1407963Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med. 2014;371(15):1392–1406. doi: 10.1056/NEJMoa1407963Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323–334. doi: 10.1056/NEJMoa1515920Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323–334. doi: 10.1056/NEJMoa1515920Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744Leehey DJ, Zhang JH, Emanuele N V., Whaley-Connell A, Palevsky PM, Reilly RF, et al. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. Clin J Am Soc Nephrol. 2015;10(12):2159–2169. doi: 10.2215/CJN.02850315Leehey DJ, Zhang JH, Emanuele N V., Whaley-Connell A, Palevsky PM, Reilly RF, et al. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. Clin J Am Soc Nephrol. 2015;10(12):2159–2169. doi: 10.2215/CJN.02850315Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–615. doi: 10.1001/jama.2014.18574Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–615. doi: 10.1001/jama.2014.18574Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi: 10.1056/NEJMoa011161Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi: 10.1056/NEJMoa011161Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118(8):577–581. doi: 10.7326/0003-4819-118-8-199304150-00001Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118(8):577–581. doi: 10.7326/0003-4819-118-8-199304150-00001Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153. doi: 10.1056/NEJM200001203420301Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153. doi: 10.1056/NEJM200001203420301Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017;6(7):pii: e005428. doi: 10.1161/JAHA.116.005428Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017;6(7):pii: e005428. doi: 10.1161/JAHA.116.005428Sumida K, Molnar MZ, Potukuchi PK, George K, Thomas F, Lu JL, et al. Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. Clin J Am Soc Nephrol. 2017;12(12):1941–1949. doi: 10.2215/CJN.02720317Sumida K, Molnar MZ, Potukuchi PK, George K, Thomas F, Lu JL, et al. Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. Clin J Am Soc Nephrol. 2017;12(12):1941–1949. doi: 10.2215/CJN.02720317Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–1903. doi: 10.1056/NEJMoa1303154Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–1903. doi: 10.1056/NEJMoa1303154Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9):884–894. doi: 10.1001/jama.2015.10081Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9):884–894. doi: 10.1001/jama.2015.10081Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105–2114. doi: 10.1093/eurheartj/ehw132Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105–2114. doi: 10.1093/eurheartj/ehw132Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane database Syst Rev. 2014;(6):CD007333. doi: 10.1002/14651858.CD007333.pub2Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane database Syst Rev. 2014;(6):CD007333. doi: 10.1002/14651858.CD007333.pub2Аветисов СЭ, Егоров ЕА, Мошетова ЛК, Нероев ВВ, Тахчиди ХП. Офтальмология. Национальное руководство. Краткое издание. Москва: ГЭОТАР-Медиа; 2014; 736 с.Аветисов СЭ, Егоров ЕА, Мошетова ЛК, Нероев ВВ, Тахчиди ХП. Офтальмология. Национальное руководство. Краткое издание. Москва: ГЭОТАР-Медиа; 2014; 736 с.Giusti C GP. Advances in biochemical mechanisms of diabetic retinopathy. Eur Rev Med Pharmacol Sci [Internet]. 2007;11(3):115–163.Giusti C GP. Advances in biochemical mechanisms of diabetic retinopathy. Eur Rev Med Pharmacol Sci [Internet]. 2007;11(3):115–163.Липатов ДВ, Викулова ОК, Железнякова АВ, Исаков МА, Бессмертная ЕГ, Толкачева АА, et al. Эпидемиология диабетической ретинопатии в Российской Федерации по данным Федерального регистра пациентов с сахарным диабетом (2013-2016 гг.). Сахарный диабет [Internet]. 2018;21(4):230–240. doi: 10.14341/DM9797Липатов ДВ, Викулова ОК, Железнякова АВ, Исаков МА, Бессмертная ЕГ, Толкачева АА, et al. Эпидемиология диабетической ретинопатии в Российской Федерации по данным Федерального регистра пациентов с сахарным диабетом (2013-2016 гг.). Сахарный диабет [Internet]. 2018;21(4):230–240. doi: 10.14341/DM9797Kohner E, Porta M, Hyer S. The pathogenesis of diabetic retinopathy and cataract. In: Pickup JC, Williams G, editors. Textbook of diabetes [Internet]. Oxford: Blackwell Scientific; 1991; p. 564–574.Kohner E, Porta M, Hyer S. The pathogenesis of diabetic retinopathy and cataract. In: Pickup JC, Williams G, editors. Textbook of diabetes [Internet]. Oxford: Blackwell Scientific; 1991; p. 564–574.Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol (Chicago, Ill 1960). 1985;103(12):1796–1806.Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol (Chicago, Ill 1960). 1985;103(12):1796–1806.Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VII. Diabetic nonproliferative retinal lesions. Ophthalmology. 1987;94(11):1389–1400. doi: 10.1016/s0161-6420(87)33275-0Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. VII. Diabetic nonproliferative retinal lesions. Ophthalmology. 1987;94(11):1389–1400. doi: 10.1016/s0161-6420(87)33275-0Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989;107(2):244–249. doi: 10.1001/archopht.1989.01070010250031Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989;107(2):244–249. doi: 10.1001/archopht.1989.01070010250031American Diabetes Association. Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers. Clin Diabetes. 2019;37(1):11–34. doi: 10.2337/cd18-0105American Diabetes Association. Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers. Clin Diabetes. 2019;37(1):11–34. doi: 10.2337/cd18-0105Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi: 10.1159/000458539Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi: 10.1159/000458539Mohamed Q, Gillies MC, Wong TY. Management of Diabetic Retinopathy: a systematic review. JAMA. 2007;298(8):902–916. doi: 10.1001/jama.298.8.902Mohamed Q, Gillies MC, Wong TY. Management of Diabetic Retinopathy: a systematic review. JAMA. 2007;298(8):902–916. doi: 10.1001/jama.298.8.902Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412–418. doi: 10.2337/dc16-2641Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412–418. doi: 10.2337/dc16-2641Virgili G, Menchini F, Murro V, Peluso E, Rosa F, Casazza G. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane database Syst Rev. 2011;(7):CD008081. doi: 10.1002/14651858.CD008081.pub2Virgili G, Menchini F, Murro V, Peluso E, Rosa F, Casazza G. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane database Syst Rev. 2011;(7):CD008081. doi: 10.1002/14651858.CD008081.pub2Virgili G, Menchini F, Dimastrogiovanni AF, Rapizzi E, Menchini U, Bandello F, et al. Optical Coherence Tomography versus Stereoscopic Fundus Photography or Biomicroscopy for Diagnosing Diabetic Macular Edema: A Systematic Review. Investig Opthalmology Vis Sci. 2007;48(11):4963–4973. doi: 10.1167/iovs.06-1472Virgili G, Menchini F, Dimastrogiovanni AF, Rapizzi E, Menchini U, Bandello F, et al. Optical Coherence Tomography versus Stereoscopic Fundus Photography or Biomicroscopy for Diagnosing Diabetic Macular Edema: A Systematic Review. Investig Opthalmology Vis Sci. 2007;48(11):4963–4973. doi: 10.1167/iovs.06-1472Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF. Antioxidant nutrient intake and diabetic retinopathy. Ophthalmology. 1998;105(12):2264–2270. doi: 10.1016/S0161-6420(98)91227-1Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF. Antioxidant nutrient intake and diabetic retinopathy. Ophthalmology. 1998;105(12):2264–2270. doi: 10.1016/S0161-6420(98)91227-1Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88(7):583–600.Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88(7):583–600.Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TME, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–1697. doi: 10.1016/S0140-6736(07)61607-9Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TME, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–1697. doi: 10.1016/S0140-6736(07)61607-9Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE Study. Ophthalmology. 2011;118(4):615–625. doi: 10.1016/j.ophtha.2011.01.031Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE Study. Ophthalmology. 2011;118(4):615–625. doi: 10.1016/j.ophtha.2011.01.031Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, et al. Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2011;118(4):609–614. doi: 10.1016/j.ophtha.2010.12.033Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, et al. Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2011;118(4):609–614. doi: 10.1016/j.ophtha.2010.12.033Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2012;119(4):789–801. doi: 10.1016/j.ophtha.2011.12.039Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2012;119(4):789–801. doi: 10.1016/j.ophtha.2011.12.039World Health Organization. Prevention of blindness from diabetes mellitus. Report of a WHO consultation. Geneva; 2006;World Health Organization. Prevention of blindness from diabetes mellitus. Report of a WHO consultation. Geneva; 2006;Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123(6):1351–1359. doi: 10.1016/j.ophtha.2016.02.022Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016;123(6):1351–1359. doi: 10.1016/j.ophtha.2016.02.022Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. doi: 10.1056/NEJM199309303291401Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. doi: 10.1056/NEJM199309303291401Thompson JT, de Bustros S, Michels RG, Rice TA. Results and Prognostic Factors in Vitrectomy for Diabetic Traction Retinal Detachment of the Macula. Arch Ophthalmol. 1987;105(4):497–502. doi: 10.1001/archopht.1987.01060040067035Thompson JT, de Bustros S, Michels RG, Rice TA. Results and Prognostic Factors in Vitrectomy for Diabetic Traction Retinal Detachment of the Macula. Arch Ophthalmol. 1987;105(4):497–502. doi: 10.1001/archopht.1987.01060040067035Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR, UK Prospective Diabetes Study (IKPDS) Group. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18(3):178–184. doi: 10.1046/j.1464-5491.2001.00458.xKohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR, UK Prospective Diabetes Study (IKPDS) Group. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18(3):178–184. doi: 10.1046/j.1464-5491.2001.00458.xShichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–B29.Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–B29.Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122(11):1631–1640. doi: 10.1001/archopht.122.11.1631Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122(11):1631–1640. doi: 10.1001/archopht.122.11.1631Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–B64.Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–B64.Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–1097. doi: 10.1046/j.1523-1755.2002.00213.xSchrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086–1097. doi: 10.1046/j.1523-1755.2002.00213.xACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244. doi: 10.1056/NEJMoa1001288ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–244. doi: 10.1056/NEJMoa1001288Do D V, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. Cochrane database Syst Rev. 2015;1:CD006127. doi: 10.1002/14651858.CD006127.pub2Do D V, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. Cochrane database Syst Rev. 2015;1:CD006127. doi: 10.1002/14651858.CD006127.pub2Misra A, Bachmann MO, Greenwood RH, Jenkins C, Shaw A, Barakat O, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med. 2009;26(10):1040–1047. doi: 10.1111/j.1464-5491.2009.02820.xMisra A, Bachmann MO, Greenwood RH, Jenkins C, Shaw A, Barakat O, et al. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. Diabet Med. 2009;26(10):1040–1047. doi: 10.1111/j.1464-5491.2009.02820.xPop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi: 10.2337/dc16-2042Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi: 10.2337/dc16-2042Старостина ЕГ. Диабетическая нейропатия: некоторые вопросы дифференциальной диагностики и системной терапии болевого синдрома. РМЖ [Internet]. 2017;(22):1665–1676.Старостина ЕГ. Диабетическая нейропатия: некоторые вопросы дифференциальной диагностики и системной терапии болевого синдрома. РМЖ [Internet]. 2017;(22):1665–1676.Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138(1):43–52. doi: 10.1093/brain/awu307Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138(1):43–52. doi: 10.1093/brain/awu307Callaghan BC, Kerber KA, Lisabeth LL, Morgenstern LB, Longoria R, Rodgers A, et al. Role of Neurologists and Diagnostic Tests on the Management of Distal Symmetric Polyneuropathy. JAMA Neurol. 2014;71(9):1143–1149. doi: 10.1001/jamaneurol.2014.1279Callaghan BC, Kerber KA, Lisabeth LL, Morgenstern LB, Longoria R, Rodgers A, et al. Role of Neurologists and Diagnostic Tests on the Management of Distal Symmetric Polyneuropathy. JAMA Neurol. 2014;71(9):1143–1149. doi: 10.1001/jamaneurol.2014.1279Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels G-J, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–628. doi: 10.1002/dmrr.1226Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels G-J, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–628. doi: 10.1002/dmrr.1226Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care. 2002;25(11):2048–2052. doi: 10.2337/diacare.25.11.2048Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care. 2002;25(11):2048–2052. doi: 10.2337/diacare.25.11.2048Bastyr EJ, Price KL, Bril V, MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005;27(8):1278–1294. doi: 10.1016/j.clinthera.2005.08.002Bastyr EJ, Price KL, Bril V, MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005;27(8):1278–1294. doi: 10.1016/j.clinthera.2005.08.002Xiong Q, Lu B, Ye H, Wu X, Zhang T, Li Y. The Diagnostic Value of Neuropathy Symptom and Change Score, Neuropathy Impairment Score and Michigan Neuropathy Screening Instrument for Diabetic Peripheral Neuropathy. Eur Neurol. 2015;74(5–6):323–327. doi: 10.1159/000441449Xiong Q, Lu B, Ye H, Wu X, Zhang T, Li Y. The Diagnostic Value of Neuropathy Symptom and Change Score, Neuropathy Impairment Score and Michigan Neuropathy Screening Instrument for Diabetic Peripheral Neuropathy. Eur Neurol. 2015;74(5–6):323–327. doi: 10.1159/000441449Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. doi: 10.1016/S0140-6736(10)60576-4Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. doi: 10.1016/S0140-6736(10)60576-4Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, et al. Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care. 2013;36(10):3208–3215. doi: 10.2337/dc13-0012Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, et al. Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care. 2013;36(10):3208–3215. doi: 10.2337/dc13-0012Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, et al. Peripheral Neuropathy in Adolescents and Young Adults With Type 1 and Type 2 Diabetes From the SEARCH for Diabetes in Youth Follow-up Cohort: A pilot study. Diabetes Care. 2013;36(12):3903–3908. doi: 10.2337/dc13-1213Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, et al. Peripheral Neuropathy in Adolescents and Young Adults With Type 1 and Type 2 Diabetes From the SEARCH for Diabetes in Youth Follow-up Cohort: A pilot study. Diabetes Care. 2013;36(12):3903–3908. doi: 10.2337/dc13-1213Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150–154.Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150–154.Spallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012;29(5):578–585. doi: 10.1111/j.1464-5491.2011.03500.xSpallone V, Morganti R, D’Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012;29(5):578–585. doi: 10.1111/j.1464-5491.2011.03500.xPham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care. 2000;23(5):606–611. doi: 10.2337/diacare.23.5.606Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care. 2000;23(5):606–611. doi: 10.2337/diacare.23.5.606Apfel SC, Asbury AK, Bril V, Burns TM, Campbell JN, Chalk CH, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001;189(1–2):3–5.Apfel SC, Asbury AK, Bril V, Burns TM, Campbell JN, Chalk CH, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001;189(1–2):3–5.Kim Y, Kim H, Choi S, Park Y, Lee S, Cho B. Clinical Usefulness of the Two-site Semmes-Weinstein Monofilament Test for Detecting Diabetic Peripheral Neuropathy. J Korean Med Sci. 2003;18(1):103–107. doi: 10.3346/jkms.2003.18.1.103Kim Y, Kim H, Choi S, Park Y, Lee S, Cho B. Clinical Usefulness of the Two-site Semmes-Weinstein Monofilament Test for Detecting Diabetic Peripheral Neuropathy. J Korean Med Sci. 2003;18(1):103–107. doi: 10.3346/jkms.2003.18.1.103Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24(2):250–256. doi: 10.2337/diacare.24.2.250Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24(2):250–256. doi: 10.2337/diacare.24.2.250Perkins BA, Orszag A, Ngo M, Ng E, New P, Bril V. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. Diabetes Care. 2010;33(7):1549–1554. doi: 10.2337/dc09-1835Perkins BA, Orszag A, Ngo M, Ng E, New P, Bril V. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. Diabetes Care. 2010;33(7):1549–1554. doi: 10.2337/dc09-1835Dyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJB, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve. 2010;42(2):157–164. doi: 10.1002/mus.21661Dyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJB, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve. 2010;42(2):157–164. doi: 10.1002/mus.21661Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33(10):2285–2293. doi: 10.2337/dc10-1303Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33(10):2285–2293. doi: 10.2337/dc10-1303Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy. Diabetes Care. 1994;17(11):1281–1289. doi: 10.2337/diacare.17.11.1281Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy. Diabetes Care. 1994;17(11):1281–1289. doi: 10.2337/diacare.17.11.1281Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131(7):1912–1925. doi: 10.1093/brain/awn093Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131(7):1912–1925. doi: 10.1093/brain/awn093Kallinikos P, Berhanu M, O’Donnell C, Boulton AJM, Efron N, Malik RA. Corneal Nerve Tortuosity in Diabetic Patients with Neuropathy. Investig Opthalmology Vis Sci. 2004;45(2):418–422. doi: 10.1167/iovs.03-0637Kallinikos P, Berhanu M, O’Donnell C, Boulton AJM, Efron N, Malik RA. Corneal Nerve Tortuosity in Diabetic Patients with Neuropathy. Investig Opthalmology Vis Sci. 2004;45(2):418–422. doi: 10.1167/iovs.03-0637Singleton JR, Smith AG, Bromberg MB. Increased Prevalence of Impaired Glucose Tolerance in Patients With Painful Sensory Neuropathy. Diabetes Care. 2001;24(8):1448–1453. doi: 10.2337/diacare.24.8.1448Singleton JR, Smith AG, Bromberg MB. Increased Prevalence of Impaired Glucose Tolerance in Patients With Painful Sensory Neuropathy. Diabetes Care. 2001;24(8):1448–1453. doi: 10.2337/diacare.24.8.1448Bongaerts BWC, Rathmann W, Heier M, Kowall B, Herder C, Stöckl D, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013;36(5):1141–1146. doi: 10.2337/dc12-0744Bongaerts BWC, Rathmann W, Heier M, Kowall B, Herder C, Stöckl D, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study. Diabetes Care. 2013;36(5):1141–1146. doi: 10.2337/dc12-0744Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials. Curr Diab Rep. 2014;14(9):528. doi: 10.1007/s11892-014-0528-7Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials. Curr Diab Rep. 2014;14(9):528. doi: 10.1007/s11892-014-0528-7Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216–223. doi: 10.1016/j.jdiacomp.2005.07.005Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20(4):216–223. doi: 10.1016/j.jdiacomp.2005.07.005Chantelau EA, Grützner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly. 2014;144:w13948. doi: 10.4414/smw.2014.13948Chantelau EA, Grützner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly. 2014;144:w13948. doi: 10.4414/smw.2014.13948Удовиченко ОВ, Бублик ЕВ, Максимова НВ, Пряхина КЮ, Ермолаева ОС, Спруит П, и др. Эффективность иммобилизирующих разгрузочных повязок Total Contact Cast: обзор зарубежных рандомизированных клинических исследований и собственные данные. Сахарный диабет [Internet]. 2010;13(2):50–55. doi: 10.14341/2072-0351-5674Удовиченко ОВ, Бублик ЕВ, Максимова НВ, Пряхина КЮ, Ермолаева ОС, Спруит П, и др. Эффективность иммобилизирующих разгрузочных повязок Total Contact Cast: обзор зарубежных рандомизированных клинических исследований и собственные данные. Сахарный диабет [Internet]. 2010;13(2):50–55. doi: 10.14341/2072-0351-5674Molines L, Darmon P, Raccah D. Charcot’s foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab. 2010;36(4):251–255. doi: 10.1016/j.diabet.2010.04.002Molines L, Darmon P, Raccah D. Charcot’s foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab. 2010;36(4):251–255. doi: 10.1016/j.diabet.2010.04.002Chantelau EA, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging--a review of 71 cases. Swiss Med Wkly. 2013;143:w13831. doi: 10.4414/smw.2013.13831Chantelau EA, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging--a review of 71 cases. Swiss Med Wkly. 2013;143:w13831. doi: 10.4414/smw.2013.13831Schaper NC, Apelqvist J, Bakker K. Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia. 2012;55(7):1869–1872. doi: 10.1007/s00125-012-2588-zSchaper NC, Apelqvist J, Bakker K. Reducing lower leg amputations in diabetes: a challenge for patients, healthcare providers and the healthcare system. Diabetologia. 2012;55(7):1869–1872. doi: 10.1007/s00125-012-2588-zSnyder RJ, Kirsner RS, Warriner RA, Lavery LA, Hanft JR, Sheehan P. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage. 2010;56(4 Suppl):S1-24.Snyder RJ, Kirsner RS, Warriner RA, Lavery LA, Hanft JR, Sheehan P. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage. 2010;56(4 Suppl):S1-24.Martín Noguerol T, Luna Alcalá A, Beltrán LS, Gómez Cabrera M, Broncano Cabrero J, Vilanova JC. Advanced MR Imaging Techniques for Differentiation of Neuropathic Arthropathy and Osteomyelitis in the Diabetic Foot. RadioGraphics. 2017;37(4):1161–1180. doi: 10.1148/rg.2017160101Martín Noguerol T, Luna Alcalá A, Beltrán LS, Gómez Cabrera M, Broncano Cabrero J, Vilanova JC. Advanced MR Imaging Techniques for Differentiation of Neuropathic Arthropathy and Osteomyelitis in the Diabetic Foot. RadioGraphics. 2017;37(4):1161–1180. doi: 10.1148/rg.2017160101Ertugrul BM, Lipsky BA, Savk O. Osteomyelitis or Charcot neuro-osteoarthropathy? Differentiating these disorders in diabetic patients with a foot problem. Diabet Foot Ankle. 2013;4(1):21855. doi: 10.3402/dfa.v4i0.21855Ertugrul BM, Lipsky BA, Savk O. Osteomyelitis or Charcot neuro-osteoarthropathy? Differentiating these disorders in diabetic patients with a foot problem. Diabet Foot Ankle. 2013;4(1):21855. doi: 10.3402/dfa.v4i0.21855Christensen TM, Gade-Rasmussen B, Pedersen LW, Hommel E, Holstein PE, Svendsen OL. Duration of off-loading and recurrence rate in Charcot osteo-arthropathy treated with less restrictive regimen with removable walker. J Diabetes Complications. 2012;26(5):430–434. doi: 10.1016/j.jdiacomp.2012.05.006Christensen TM, Gade-Rasmussen B, Pedersen LW, Hommel E, Holstein PE, Svendsen OL. Duration of off-loading and recurrence rate in Charcot osteo-arthropathy treated with less restrictive regimen with removable walker. J Diabetes Complications. 2012;26(5):430–434. doi: 10.1016/j.jdiacomp.2012.05.006Game FL, Catlow R, Jones GR, Edmonds ME, Jude EB, Rayman G, et al. Audit of acute Charcot’s disease in the UK: the CDUK study. Diabetologia. 2012;55(1):32–35. doi: 10.1007/s00125-011-2354-7Game FL, Catlow R, Jones GR, Edmonds ME, Jude EB, Rayman G, et al. Audit of acute Charcot’s disease in the UK: the CDUK study. Diabetologia. 2012;55(1):32–35. doi: 10.1007/s00125-011-2354-7Cavanagh PR, Bus SA. Off-loading the diabetic foot for ulcer prevention and healing. Plast Reconstr Surg. 2011;127 Suppl:248S-256S. doi: 10.1097/PRS.0b013e3182024864Cavanagh PR, Bus SA. Off-loading the diabetic foot for ulcer prevention and healing. Plast Reconstr Surg. 2011;127 Suppl:248S-256S. doi: 10.1097/PRS.0b013e3182024864Nilsson PM, Cederholm J, Zethelius BR, Eliasson BR, Eeg-Olofsson K, Gudbj Rnsdottir S. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press. 2011;20(6):348–354. doi: 10.3109/08037051.2011.587288Nilsson PM, Cederholm J, Zethelius BR, Eliasson BR, Eeg-Olofsson K, Gudbj Rnsdottir S. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press. 2011;20(6):348–354. doi: 10.3109/08037051.2011.587288Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr. Hypertension. 2018;71(6):e13–e115. doi: 10.1161/HYP.0000000000000065Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr. Hypertension. 2018;71(6):e13–e115. doi: 10.1161/HYP.0000000000000065Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals. Hypertension. 2005;45(1):142–161. doi: 10.1161/01.HYP.0000150859.47929.8ePickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals. Hypertension. 2005;45(1):142–161. doi: 10.1161/01.HYP.0000150859.47929.8ePowers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone EZ. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011;154(12):781–788. doi: 10.7326/0003-4819-154-12-201106210-00005Powers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone EZ. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011;154(12):781–788. doi: 10.7326/0003-4819-154-12-201106210-00005de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–1284. doi: 10.2337/dci17-0026de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–1284. doi: 10.2337/dci17-0026Bobrie G, Genès N, Vaur L, Clerson P, Vaisse B, Mallion JM, et al. Is “isolated home” hypertension as opposed to “isolated office” hypertension a sign of greater cardiovascular risk? Arch Intern Med. 2001;161(18):2205–2211.Bobrie G, Genès N, Vaur L, Clerson P, Vaisse B, Mallion JM, et al. Is “isolated home” hypertension as opposed to “isolated office” hypertension a sign of greater cardiovascular risk? Arch Intern Med. 2001;161(18):2205–2211.Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111(14):1777–1783. doi: 10.1161/01.CIR.0000160923.04524.5BSega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111(14):1777–1783. doi: 10.1161/01.CIR.0000160923.04524.5BArguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane database Syst Rev. 2013;(10):CD008277. doi: 10.1002/14651858.CD008277.pub2Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane database Syst Rev. 2013;(10):CD008277. doi: 10.1002/14651858.CD008277.pub2Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. doi: 10.1136/bmj.i717Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. doi: 10.1136/bmj.i717Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142–148. doi: 10.1111/j.1464-5491.2008.02640.xBulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142–148. doi: 10.1111/j.1464-5491.2008.02640.xDickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook J V, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215–233. doi: 10.1097/01.hjh.0000199800.72563.26Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook J V, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215–233. doi: 10.1097/01.hjh.0000199800.72563.26Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, et al. Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension. Hypertension. 2009;54(3):475–481. doi: 10.1161/HYPERTENSIONAHA.109.131235Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, et al. Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension. Hypertension. 2009;54(3):475–481. doi: 10.1161/HYPERTENSIONAHA.109.131235Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5):1189–1196. doi: 10.3945/ajcn.2010.29673Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5):1189–1196. doi: 10.3945/ajcn.2010.29673Flegal KM, Kit BK, Orpana H, Graubard BI. Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories. JAMA. 2013;309(1):71–82. doi: 10.1001/jama.2012.113905Flegal KM, Kit BK, Orpana H, Graubard BI. Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories. JAMA. 2013;309(1):71–82. doi: 10.1001/jama.2012.113905Cushman WC, Cutler JA, Hanna E, Bingham SF, Follmann D, Harford T, et al. Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med. 1998;158(11):1197–1207.Cushman WC, Cutler JA, Hanna E, Bingham SF, Follmann D, Harford T, et al. Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med. 1998;158(11):1197–1207.Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ. 1994;309(6959):901–911. doi: 10.1136/bmj.309.6959.901Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ. 1994;309(6959):901–911. doi: 10.1136/bmj.309.6959.901Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of Resistance Training on Blood Pressure and Other Cardiovascular Risk Factors. Hypertension. 2011;58(5):950–958. doi: 10.1161/HYPERTENSIONAHA.111.177071Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of Resistance Training on Blood Pressure and Other Cardiovascular Risk Factors. Hypertension. 2011;58(5):950–958. doi: 10.1161/HYPERTENSIONAHA.111.177071Bakris GL, Weir MR, Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003;5(3):202–209.Bakris GL, Weir MR, Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003;5(3):202–209.Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA. 2018;320(6):566–579. doi: 10.1001/jama.2018.10359Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA. 2018;320(6):566–579. doi: 10.1001/jama.2018.10359Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC, Black H, et al. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004;6(3):116–125.Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC, Black H, et al. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004;6(3):116–125.Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56(1):77–85. doi: 10.1016/j.jacc.2010.02.046Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56(1):77–85. doi: 10.1016/j.jacc.2010.02.046Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi: 10.1093/eurheartj/eht296Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi: 10.1093/eurheartj/eht296Underwood SR, Anagnostopoulos C, Cerqueira M, Ell PJ, Flint EJ, Harbinson M, et al. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging. 2004;31(2):261–291. doi: 10.1007/s00259-003-1344-5Underwood SR, Anagnostopoulos C, Cerqueira M, Ell PJ, Flint EJ, Harbinson M, et al. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging. 2004;31(2):261–291. doi: 10.1007/s00259-003-1344-5Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; doi: 10.1093/eurheartj/ehz486Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; doi: 10.1093/eurheartj/ehz486Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007;30(10):2729–2736. doi: 10.2337/dc07-9927Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007;30(10):2729–2736. doi: 10.2337/dc07-9927Meyers DG, Neuberger JS, He J. Cardiovascular Effect of Bans on Smoking in Public Places. J Am Coll Cardiol. 2009;54(14):1249–1255. doi: 10.1016/j.jacc.2009.07.022Meyers DG, Neuberger JS, He J. Cardiovascular Effect of Bans on Smoking in Public Places. J Am Coll Cardiol. 2009;54(14):1249–1255. doi: 10.1016/j.jacc.2009.07.022World Health Organization. IARC Handbooks of Cancer Prevention, Tobacco Control, vol. 14: Effectiveness of Tax and Price Policies for Tobacco Control. Lyon; 2011; 366 p.World Health Organization. IARC Handbooks of Cancer Prevention, Tobacco Control, vol. 14: Effectiveness of Tax and Price Policies for Tobacco Control. Lyon; 2011; 366 p.Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane database Syst Rev. 2004;(1):CD003041. doi: 10.1002/14651858.CD003041.pub2Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane database Syst Rev. 2004;(1):CD003041. doi: 10.1002/14651858.CD003041.pub2Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med. 2013;368(14):1279–1290. doi: 10.1056/NEJMoa1200303Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med. 2013;368(14):1279–1290. doi: 10.1056/NEJMoa1200303Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988;260(14):2088–2093.Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988;260(14):2088–2093.Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225. doi: 10.1093/eurheartj/ehi115Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225. doi: 10.1093/eurheartj/ehi115Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571–1582. doi: 10.1161/CIRCULATIONAHA.117.030950Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571–1582. doi: 10.1161/CIRCULATIONAHA.117.030950Zhang X-L, Zhu Q-Q, Zhu L, Chen J-Z, Chen Q-H, Li G-N, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13(1):123. doi: 10.1186/s12916-015-0358-8Zhang X-L, Zhu Q-Q, Zhu L, Chen J-Z, Chen Q-H, Li G-N, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13(1):123. doi: 10.1186/s12916-015-0358-8ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574. doi: 10.1056/NEJMoa1001282ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574. doi: 10.1056/NEJMoa1001282Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. doi: 10.1136/bmj.324.7329.71Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. doi: 10.1136/bmj.324.7329.71Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340(8833):1421–1425. doi: 10.1016/0140-6736(92)92619-qJuul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340(8833):1421–1425. doi: 10.1016/0140-6736(92)92619-qValgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213–260. doi: 10.1093/eurheartj/ehx419Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213–260. doi: 10.1093/eurheartj/ehx419Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67(23):2732–2740. doi: 10.1016/j.jacc.2016.03.529Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67(23):2732–2740. doi: 10.1016/j.jacc.2016.03.529Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–293. doi: 10.1016/S0140-6736(09)62191-7Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–293. doi: 10.1016/S0140-6736(09)62191-7Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319–1330. doi: 10.1056/NEJMoa1709118Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319–1330. doi: 10.1056/NEJMoa1709118BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–2515. doi: 10.1056/NEJMoa0805796BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–2515. doi: 10.1056/NEJMoa0805796Abdallah MS, Wang K, Magnuson EA, Spertus JA, Farkouh ME, Fuster V, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA. 2013;310(15):1581–1590. doi: 10.1001/jama.2013.279208Abdallah MS, Wang K, Magnuson EA, Spertus JA, Farkouh ME, Fuster V, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA. 2013;310(15):1581–1590. doi: 10.1001/jama.2013.279208Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. doi: 10.1093/eurheartj/ehy394Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. doi: 10.1093/eurheartj/ehy394Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267–315. doi: 10.1093/eurheartj/ehv320Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267–315. doi: 10.1093/eurheartj/ehv320Senthinathan A, Kelly V, Dzingina M, Jones D, Baker M, Longson D, et al. Hyperglycaemia in acute coronary syndromes: summary of NICE guidance. BMJ. 2011;343:d6646. doi: 10.1136/bmj.d6646Senthinathan A, Kelly V, Dzingina M, Jones D, Baker M, Longson D, et al. Hyperglycaemia in acute coronary syndromes: summary of NICE guidance. BMJ. 2011;343:d6646. doi: 10.1136/bmj.d6646Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–1311. doi: 10.2337/dc12-0719Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–1311. doi: 10.2337/dc12-0719Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393Hernandez A V., Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus. Am J Cardiovasc Drugs. 2011;11(2):115–128. doi: 10.2165/11587580-000000000-00000Hernandez A V., Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus. Am J Cardiovasc Drugs. 2011;11(2):115–128. doi: 10.2165/11587580-000000000-00000Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824–831. doi: 10.1093/eurheartj/ehp604Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824–831. doi: 10.1093/eurheartj/ehp604Мареев ВЮ, Фомин ИВ, Агеев ФТ, Беграмбекова ЮЛ, Васюк ЮА, Гарганеева АА, et al. Сердечная недостаточность: хроническая и острая декомпенсированная. Диагностика, профилактика и лечение. Кардиология [Internet]. 2018;58(6S):8–158. doi: 10.18087/cardio.2475Мареев ВЮ, Фомин ИВ, Агеев ФТ, Беграмбекова ЮЛ, Васюк ЮА, Гарганеева АА, et al. Сердечная недостаточность: хроническая и острая декомпенсированная. Диагностика, профилактика и лечение. Кардиология [Internet]. 2018;58(6S):8–158. doi: 10.18087/cardio.2475Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2017;70(6):776–803. doi: 10.1016/j.jacc.2017.04.025Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2017;70(6):776–803. doi: 10.1016/j.jacc.2017.04.025Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018;200:83–89. doi: 10.1016/j.ahj.2018.01.012Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018;200:83–89. doi: 10.1016/j.ahj.2018.01.012McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). Eur J Heart Fail. 2019;21(5):665–675. doi: 10.1002/ejhf.1432McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). Eur J Heart Fail. 2019;21(5):665–675. doi: 10.1002/ejhf.1432Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure. Circ Hear Fail. 2013;6(3):395–402. doi: 10.1161/CIRCHEARTFAILURE.112.000162Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure. Circ Hear Fail. 2013;6(3):395–402. doi: 10.1161/CIRCHEARTFAILURE.112.000162Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L V., et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–2257. doi: 10.1056/NEJMoa1509225Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L V., et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–2257. doi: 10.1056/NEJMoa1509225Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228–1239. doi: 10.1056/NEJMoa1612917Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228–1239. doi: 10.1056/NEJMoa1612917Azoulay L, Suissa S. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. Diabetes Care. 2017;40(5):706–714. doi: 10.2337/dc16-1943Azoulay L, Suissa S. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. Diabetes Care. 2017;40(5):706–714. doi: 10.2337/dc16-1943Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111(5):583–590. doi: 10.1161/01.CIR.0000154542.13412.B1Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111(5):583–590. doi: 10.1161/01.CIR.0000154542.13412.B1Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–2351. doi: 10.2337/diacare.28.10.2345Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–2351. doi: 10.2337/diacare.28.10.2345Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076. doi: 10.1016/S0140-6736(14)62225-XZannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076. doi: 10.1016/S0140-6736(14)62225-XGreen JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79. doi: 10.1001/jama.2018.18269Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79. doi: 10.1001/jama.2018.18269Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50(1):18–25. doi: 10.1007/s00125-006-0491-1Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50(1):18–25. doi: 10.1007/s00125-006-0491-1Morbach S, Furchert H, Gröblinghoff U, Hoffmeier H, Kersten K, Klauke G-T, et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012;35(10):2021–2027. doi: 10.2337/dc12-0200Morbach S, Furchert H, Gröblinghoff U, Hoffmeier H, Kersten K, Klauke G-T, et al. Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade. Diabetes Care. 2012;35(10):2021–2027. doi: 10.2337/dc12-0200National Institute for Health and Clinical Excellence. Diabetic Foot Problems. Inpatient management of diabetic foot problems. London; 2011;National Institute for Health and Clinical Excellence. Diabetic Foot Problems. Inpatient management of diabetic foot problems. London; 2011;Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial calcification and diabetic neuropathy. BMJ. 1982;284(6320):928–930. doi: 10.1136/bmj.284.6320.928Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial calcification and diabetic neuropathy. BMJ. 1982;284(6320):928–930. doi: 10.1136/bmj.284.6320.928Feinglass J, Shively VP, Martin GJ, Huang ME, Soriano RH, Rodriguez HE, et al. How “preventable” are lower extremity amputations? A qualitative study of patient perceptions of precipitating factors. Disabil Rehabil. 2012;34(25):2158–2165. doi: 10.3109/09638288.2012.677936Feinglass J, Shively VP, Martin GJ, Huang ME, Soriano RH, Rodriguez HE, et al. How “preventable” are lower extremity amputations? A qualitative study of patient perceptions of precipitating factors. Disabil Rehabil. 2012;34(25):2158–2165. doi: 10.3109/09638288.2012.677936Sumpio BE, Armstrong DG, Lavery LA, Andros G, SVS/APMA writing group. The role of interdisciplinary team approach in the management of the diabetic foot: a joint statement from the Society for Vascular Surgery and the American Podiatric Medical Association. J Vasc Surg. 2010;51(6):1504–1506. doi: 10.1016/j.jvs.2010.04.010Sumpio BE, Armstrong DG, Lavery LA, Andros G, SVS/APMA writing group. The role of interdisciplinary team approach in the management of the diabetic foot: a joint statement from the Society for Vascular Surgery and the American Podiatric Medical Association. J Vasc Surg. 2010;51(6):1504–1506. doi: 10.1016/j.jvs.2010.04.010Ababneh M, Al Ayed MY, Robert AA, Al Dawish MA. Clinical Utility of the Ankle-Brachial Index and Toe Brachial Index in Patients with Diabetic Foot Ulcers. Curr Diabetes Rev. 2019;15. doi: 10.2174/1573399815666190531093238Ababneh M, Al Ayed MY, Robert AA, Al Dawish MA. Clinical Utility of the Ankle-Brachial Index and Toe Brachial Index in Patients with Diabetic Foot Ulcers. Curr Diabetes Rev. 2019;15. doi: 10.2174/1573399815666190531093238Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol. 2000;19(1 Suppl 1):1–304.Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol. 2000;19(1 Suppl 1):1–304.Huen KH, Chowdhury R, Shafii SM, Brewster LP, Arya S, Duwayri Y, et al. Smoking Cessation Is the Least Successful Outcome of Risk Factor Modification in Uninsured Patients with Symptomatic Peripheral Arterial Disease. Ann Vasc Surg. 2015;29(1):42–49. doi: 10.1016/j.avsg.2014.09.014Huen KH, Chowdhury R, Shafii SM, Brewster LP, Arya S, Duwayri Y, et al. Smoking Cessation Is the Least Successful Outcome of Risk Factor Modification in Uninsured Patients with Symptomatic Peripheral Arterial Disease. Ann Vasc Surg. 2015;29(1):42–49. doi: 10.1016/j.avsg.2014.09.014The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222. doi: 10.1016/S0140-6736(10)60484-9The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222. doi: 10.1016/S0140-6736(10)60484-9Rickels MR, Mueller R, Teff KL, Naji A. β-cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab. 2010;95(3):1238–1246. doi: 10.1210/jc.2009-2289Rickels MR, Mueller R, Teff KL, Naji A. β-cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab. 2010;95(3):1238–1246. doi: 10.1210/jc.2009-2289Российское общество ангиологов и сосудистых хирургов, Ассоциация сердечно-сосудистых хирургов России, Российское научное общество рентгенэндоваскулярных хирургов и интервенционных радиологов, Всероссийское научное общество кардиологов, Ассоциация флебологов России. Национальные рекомендации по ведению пациентов с заболеваниями артерий нижних конечностей. Москва; 2013;Российское общество ангиологов и сосудистых хирургов, Ассоциация сердечно-сосудистых хирургов России, Российское научное общество рентгенэндоваскулярных хирургов и интервенционных радиологов, Всероссийское научное общество кардиологов, Ассоциация флебологов России. Национальные рекомендации по ведению пациентов с заболеваниями артерий нижних конечностей. Москва; 2013;Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representati. G Ital Cardiol (Rome). 2017;18(7):547–612. doi: 10.1714/2729.27821Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representati. G Ital Cardiol (Rome). 2017;18(7):547–612. doi: 10.1714/2729.27821Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA, et al. IWGDF Guidelines on the prevention and management of diabetic foot disease. 2019;Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA, et al. IWGDF Guidelines on the prevention and management of diabetic foot disease. 2019;Collins R, Burch J, Cranny G, Aguiar-Ibáñez R, Craig D, Wright K, et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. BMJ. 2007;334(7606):1257. doi: 10.1136/bmj.39217.473275.55Collins R, Burch J, Cranny G, Aguiar-Ibáñez R, Craig D, Wright K, et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. BMJ. 2007;334(7606):1257. doi: 10.1136/bmj.39217.473275.55Dominguez A, Bahadorani J, Reeves R, Mahmud E, Patel M. Endovascular therapy for critical limb ischemia. Expert Rev Cardiovasc Ther. 2015;13(4):429–444. doi: 10.1586/14779072.2015.1019472Dominguez A, Bahadorani J, Reeves R, Mahmud E, Patel M. Endovascular therapy for critical limb ischemia. Expert Rev Cardiovasc Ther. 2015;13(4):429–444. doi: 10.1586/14779072.2015.1019472Manzi M, Palena L, Cester G. Endovascular techniques for limb salvage in diabetics with crural and pedal disease. J Cardiovasc Surg (Torino). 2011;52(4):485–492.Manzi M, Palena L, Cester G. Endovascular techniques for limb salvage in diabetics with crural and pedal disease. J Cardiovasc Surg (Torino). 2011;52(4):485–492.Belch JJF, Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833.e2. doi: 10.1016/j.jvs.2010.04.027Belch JJF, Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833.e2. doi: 10.1016/j.jvs.2010.04.027Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2008;30(2):192–201. doi: 10.1093/eurheartj/ehn534Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2008;30(2):192–201. doi: 10.1093/eurheartj/ehn534Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. doi: 10.1093/eurheartj/ehx095Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. doi: 10.1093/eurheartj/ehx095Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. doi: 10.1016/S0140-6736(17)32409-1Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. doi: 10.1016/S0140-6736(17)32409-1Kronlage M, Blessing E, Müller OJ, Heilmeier B, Katus HA, Erbel C. Anticoagulation in addition to dual antiplatelet therapy has no impact on long-term follow-up after endovascular treatment of (sub)acute lower limb ischemia. Vasa. 2019;48(4):321–329. doi: 10.1024/0301-1526/a000786Kronlage M, Blessing E, Müller OJ, Heilmeier B, Katus HA, Erbel C. Anticoagulation in addition to dual antiplatelet therapy has no impact on long-term follow-up after endovascular treatment of (sub)acute lower limb ischemia. Vasa. 2019;48(4):321–329. doi: 10.1024/0301-1526/a000786Guerin A, Nisenbaum R, Ray JG. Use of Maternal GHb Concentration to Estimate the Risk of Congenital Anomalies in the Offspring of Women with Prepregnancy Diabetes. Diabetes Care. 2007;30(7):1920–1925. doi: 10.2337/dc07-0278Guerin A, Nisenbaum R, Ray JG. Use of Maternal GHb Concentration to Estimate the Risk of Congenital Anomalies in the Offspring of Women with Prepregnancy Diabetes. Diabetes Care. 2007;30(7):1920–1925. doi: 10.2337/dc07-0278Lowe LP, Metzger BE, Dyer AR, Lowe J, McCance DR, Lappin TRJ, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: Associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care. 2012;35(3):574–580. doi: 10.2337/dc11-1687Lowe LP, Metzger BE, Dyer AR, Lowe J, McCance DR, Lappin TRJ, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: Associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care. 2012;35(3):574–580. doi: 10.2337/dc11-1687Wahabi HA, Alzeidan RA, Bawazeer GA, Alansari LA, Esmaeil SA. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2010;10(1):63. doi: 10.1186/1471-2393-10-63Wahabi HA, Alzeidan RA, Bawazeer GA, Alansari LA, Esmaeil SA. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2010;10(1):63. doi: 10.1186/1471-2393-10-63Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001;94(8):435–444. doi: 10.1093/qjmed/94.8.435Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001;94(8):435–444. doi: 10.1093/qjmed/94.8.435Peterson C, Grosse SD, Li R, Sharma AJ, Razzaghi H, Herman WH, et al. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. Am J Obstet Gynecol. 2015;212(1):74.e1-74.e9. doi: 10.1016/j.ajog.2014.09.009Peterson C, Grosse SD, Li R, Sharma AJ, Razzaghi H, Herman WH, et al. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. Am J Obstet Gynecol. 2015;212(1):74.e1-74.e9. doi: 10.1016/j.ajog.2014.09.009Boulot P, Chabbert-Buffet N, D’Ercole C, Floriot M, Fontaine P, Fournier A, et al. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care. 2003;26(11):2990–2993. doi: 10.2337/diacare.26.11.2990Boulot P, Chabbert-Buffet N, D’Ercole C, Floriot M, Fontaine P, Fournier A, et al. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care. 2003;26(11):2990–2993. doi: 10.2337/diacare.26.11.2990Ekpebegh CO, Coetzee EJ, van der Merwe L, Levitt NS. A 10-year retrospective analysis of pregnancy outcome in pregestational Type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med. 2007;24(3):253–258. doi: 10.1111/j.1464-5491.2007.02053.xEkpebegh CO, Coetzee EJ, van der Merwe L, Levitt NS. A 10-year retrospective analysis of pregnancy outcome in pregestational Type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med. 2007;24(3):253–258. doi: 10.1111/j.1464-5491.2007.02053.xRoland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC. The pregnancies of women with Type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005;22(12):1774–1777. doi: 10.1111/j.1464-5491.2005.01784.xRoland JM, Murphy HR, Ball V, Northcote-Wright J, Temple RC. The pregnancies of women with Type 2 diabetes: poor outcomes but opportunities for improvement. Diabet Med. 2005;22(12):1774–1777. doi: 10.1111/j.1464-5491.2005.01784.xPollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin Glargine Safety in Pregnancy: A transplacental transfer study. Diabetes Care. 2010;33(1):29–33. doi: 10.2337/dc09-1045Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin Glargine Safety in Pregnancy: A transplacental transfer study. Diabetes Care. 2010;33(1):29–33. doi: 10.2337/dc09-1045Holcberg G, Tsadkin-Tamir M, Sapir O, Wiznizer A, Segal D, Polachek H, et al. Transfer of insulin lispro across the human placenta. Eur J Obstet Gynecol Reprod Biol. 2004;115(1):117–118. doi: 10.1016/j.ejogrb.2003.10.006Holcberg G, Tsadkin-Tamir M, Sapir O, Wiznizer A, Segal D, Polachek H, et al. Transfer of insulin lispro across the human placenta. Eur J Obstet Gynecol Reprod Biol. 2004;115(1):117–118. doi: 10.1016/j.ejogrb.2003.10.006Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of Insulin Lispro Across the Human Placenta: In vitro perfusion studies. Diabetes Care. 2003;26(5):1390–1394. doi: 10.2337/diacare.26.5.1390Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of Insulin Lispro Across the Human Placenta: In vitro perfusion studies. Diabetes Care. 2003;26(5):1390–1394. doi: 10.2337/diacare.26.5.1390Suffecool K, Rosenn B, Niederkofler EE, Kiernan UA, Foroutan J, Antwi K, et al. Insulin Detemir Does Not Cross the Human Placenta. Diabetes Care. 2015;38(2):e20–e21. doi: 10.2337/dc14-2090Suffecool K, Rosenn B, Niederkofler EE, Kiernan UA, Foroutan J, Antwi K, et al. Insulin Detemir Does Not Cross the Human Placenta. Diabetes Care. 2015;38(2):e20–e21. doi: 10.2337/dc14-2090Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy Outcome Following Exposure to Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists. Hypertension. 2012;60(2):444–450. doi: 10.1161/HYPERTENSIONAHA.112.196352Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy Outcome Following Exposure to Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Antagonists. Hypertension. 2012;60(2):444–450. doi: 10.1161/HYPERTENSIONAHA.112.196352Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350(10):h1035. doi: 10.1136/bmj.h1035Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350(10):h1035. doi: 10.1136/bmj.h1035Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, et al. Metabolic Control and Progression of Retinopathy: The Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18(5):631–637. doi: 10.2337/diacare.18.5.631Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, et al. Metabolic Control and Progression of Retinopathy: The Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18(5):631–637. doi: 10.2337/diacare.18.5.631Damm JA, Asbjornsdottir B, Callesen NF, Mathiesen JM, Ringholm L, Pedersen BW, et al. Diabetic Nephropathy and Microalbuminuria in Pregnant Women With Type 1 and Type 2 Diabetes: Prevalence, antihypertensive strategy, and pregnancy outcome. Diabetes Care. 2013;36(11):3489–3494. doi: 10.2337/dc13-1031Damm JA, Asbjornsdottir B, Callesen NF, Mathiesen JM, Ringholm L, Pedersen BW, et al. Diabetic Nephropathy and Microalbuminuria in Pregnant Women With Type 1 and Type 2 Diabetes: Prevalence, antihypertensive strategy, and pregnancy outcome. Diabetes Care. 2013;36(11):3489–3494. doi: 10.2337/dc13-1031Ringholm L, Damm JA, Vestgaard M, Damm P, Mathiesen ER. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding. Curr Diab Rep. 2016;16(2):12. doi: 10.1007/s11892-015-0705-3Ringholm L, Damm JA, Vestgaard M, Damm P, Mathiesen ER. Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding. Curr Diab Rep. 2016;16(2):12. doi: 10.1007/s11892-015-0705-3Carr DB, Koontz GL, Gardella C, Holing E V, Brateng DA, Brown ZA, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens. 2006;19(5):513–519. doi: 10.1016/j.amjhyper.2005.12.010Carr DB, Koontz GL, Gardella C, Holing E V, Brateng DA, Brown ZA, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens. 2006;19(5):513–519. doi: 10.1016/j.amjhyper.2005.12.010Nevis IF, Reitsma A, Dominic A, McDonald S, Thabane L, Akl EA, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011;6(11):2587–2598. doi: 10.2215/CJN.10841210Nevis IF, Reitsma A, Dominic A, McDonald S, Thabane L, Akl EA, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011;6(11):2587–2598. doi: 10.2215/CJN.10841210O’Neill SM, Kenny LC, Khashan AS, West HM, Smyth RM, Kearney PM. Different insulin types and regimens for pregnant women with pre-existing diabetes. Cochrane database Syst Rev. 2017;2:CD011880. doi: 10.1002/14651858.CD011880.pub2O’Neill SM, Kenny LC, Khashan AS, West HM, Smyth RM, Kearney PM. Different insulin types and regimens for pregnant women with pre-existing diabetes. Cochrane database Syst Rev. 2017;2:CD011880. doi: 10.1002/14651858.CD011880.pub2Simmons D, Thompson CF, Conroy C, Scott DJ. Use of Insulin Pumps in Pregnancies Complicated by Type 2 Diabetes and Gestational Diabetes in a Multiethnic Community. Diabetes Care. 2001;24(12):2078–2082. doi: 10.2337/diacare.24.12.2078Simmons D, Thompson CF, Conroy C, Scott DJ. Use of Insulin Pumps in Pregnancies Complicated by Type 2 Diabetes and Gestational Diabetes in a Multiethnic Community. Diabetes Care. 2001;24(12):2078–2082. doi: 10.2337/diacare.24.12.2078Murphy HR, Roland JM, Skinner TC, Simmons D, Gurnell E, Morrish NJ, et al. Effectiveness of a Regional Prepregnancy Care Program in Women With Type 1 and Type 2 Diabetes: Benefits beyond glycemic control. Diabetes Care. 2010;33(12):2514–2520. doi: 10.2337/dc10-1113Murphy HR, Roland JM, Skinner TC, Simmons D, Gurnell E, Morrish NJ, et al. Effectiveness of a Regional Prepregnancy Care Program in Women With Type 1 and Type 2 Diabetes: Benefits beyond glycemic control. Diabetes Care. 2010;33(12):2514–2520. doi: 10.2337/dc10-1113American Diabetes Association. 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes — 2019. Diabetes Care. 2019;42(Supplement 1):S81–S89. doi: 10.2337/dc19-S008American Diabetes Association. 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes — 2019. Diabetes Care. 2019;42(Supplement 1):S81–S89. doi: 10.2337/dc19-S008Abell SK, Boyle JA, de Courten B, Soldatos G, Wallace EM, Zoungas S, et al. Impact of type 2 diabetes, obesity and glycaemic control on pregnancy outcomes. Aust New Zeal J Obstet Gynaecol. 2017;57(3):308–314. doi: 10.1111/ajo.12521Abell SK, Boyle JA, de Courten B, Soldatos G, Wallace EM, Zoungas S, et al. Impact of type 2 diabetes, obesity and glycaemic control on pregnancy outcomes. Aust New Zeal J Obstet Gynaecol. 2017;57(3):308–314. doi: 10.1111/ajo.12521Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: Systematic review of observational studies. BMC Pregnancy Childbirth. 2006;6(1):30. doi: 10.1186/1471-2393-6-30Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: Systematic review of observational studies. BMC Pregnancy Childbirth. 2006;6(1):30. doi: 10.1186/1471-2393-6-30Wahabi HA, Esmaeil SA, Fayed A, Al-Shaikh G, Alzeidan RA. Pre-existing diabetes mellitus and adverse pregnancy outcomes. BMC Res Notes. 2012;5(1):496. doi: 10.1186/1756-0500-5-496Wahabi HA, Esmaeil SA, Fayed A, Al-Shaikh G, Alzeidan RA. Pre-existing diabetes mellitus and adverse pregnancy outcomes. BMC Res Notes. 2012;5(1):496. doi: 10.1186/1756-0500-5-496Taylor C, McCance DR, Chappell L, Nelson-Piercy C, Thorne SA, Ismail KMK, et al. Implementation of guidelines for multidisciplinary team management of pregnancy in women with pre-existing diabetes or cardiac conditions: results from a UK national survey. BMC Pregnancy Childbirth. 2017;17(1):434. doi: 10.1186/s12884-017-1609-9Taylor C, McCance DR, Chappell L, Nelson-Piercy C, Thorne SA, Ismail KMK, et al. Implementation of guidelines for multidisciplinary team management of pregnancy in women with pre-existing diabetes or cardiac conditions: results from a UK national survey. BMC Pregnancy Childbirth. 2017;17(1):434. doi: 10.1186/s12884-017-1609-9Tieu J, Middleton P, Crowther CA, Shepherd E. Preconception care for diabetic women for improving maternal and infant health. Cochrane database Syst Rev. 2017;8:CD007776. doi: 10.1002/14651858.CD007776.pub3Tieu J, Middleton P, Crowther CA, Shepherd E. Preconception care for diabetic women for improving maternal and infant health. Cochrane database Syst Rev. 2017;8:CD007776. doi: 10.1002/14651858.CD007776.pub3Meneilly GS, Knip A, Miller DB, Sherifali D, Tessier D, Zahedi A. Diabetes in Older People. Can J Diabetes. 2018;42(Suppl 1):S283–S295. doi: 10.1016/j.jcjd.2017.10.021Meneilly GS, Knip A, Miller DB, Sherifali D, Tessier D, Zahedi A. Diabetes in Older People. Can J Diabetes. 2018;42(Suppl 1):S283–S295. doi: 10.1016/j.jcjd.2017.10.021LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520–1574. doi: 10.1210/jc.2019-00198LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520–1574. doi: 10.1210/jc.2019-00198International Diabetes Federation Working Group. Managing older people with Type 2 Diabetes . Global Guideline. Brussels: International Diabetes Federation; 2013; 94 p.International Diabetes Federation Working Group. Managing older people with Type 2 Diabetes . Global Guideline. Brussels: International Diabetes Federation; 2013; 94 p.American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S139–S147. doi: 10.2337/dc19-S012American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S139–S147. doi: 10.2337/dc19-S012Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle H-J. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years. Diabetes Obes Metab. 2014;16(11):1078–1086. doi: 10.1111/dom.12321Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle H-J. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years. Diabetes Obes Metab. 2014;16(11):1078–1086. doi: 10.1111/dom.12321Round EM, Engel SS, Golm GT, Davies MJ, Kaufman KD, Goldstein BJ. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014;31(3):203–214. doi: 10.1007/s40266-014-0155-7Round EM, Engel SS, Golm GT, Davies MJ, Kaufman KD, Goldstein BJ. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014;31(3):203–214. doi: 10.1007/s40266-014-0155-7Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle H-J. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902):1413–1423. doi: 10.1016/S0140-6736(13)61500-7Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle H-J. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902):1413–1423. doi: 10.1016/S0140-6736(13)61500-7Karyekar CS, Ravichandran S, Allen E, Fleming D, Frederich R. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging. 2013;8:419–430. doi: 10.2147/CIA.S41246Karyekar CS, Ravichandran S, Allen E, Fleming D, Frederich R. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging. 2013;8:419–430. doi: 10.2147/CIA.S41246Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8(5):405–418. doi: 10.1016/j.amjopharm.2010.10.003Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8(5):405–418. doi: 10.1016/j.amjopharm.2010.10.003Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011;27(4):863–869. doi: 10.1185/03007995.2011.554532Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011;27(4):863–869. doi: 10.1185/03007995.2011.554532Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15(10):906–914. doi: 10.1111/dom.12102Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15(10):906–914. doi: 10.1111/dom.12102Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751–755. doi: 10.1111/j.1532-5415.1996.tb03729.xShorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751–755. doi: 10.1111/j.1532-5415.1996.tb03729.xShorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157(15):1681–1686.Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157(15):1681–1686.Greco D, Pisciotta M, Gambina F, Maggio F. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol diabetes. 2010;118(4):215–219. doi: 10.1055/s-0029-1241823Greco D, Pisciotta M, Gambina F, Maggio F. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol diabetes. 2010;118(4):215–219. doi: 10.1055/s-0029-1241823Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23(11):1792–1823.Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23(11):1792–1823.Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32–39. doi: 10.1503/cmaj.080486Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32–39. doi: 10.1503/cmaj.080486Мустафина СВ, Рымар ОД, Сазонова ОВ, Щербакова ЛВ, Воевода МИ. Валидизация финской шкалы риска «FINDRISC» на европеоидной популяции Сибири. Сахарный диабет [Internet]. 2016;19(2):113–118. doi: 10.14341/DM200418-10Мустафина СВ, Рымар ОД, Сазонова ОВ, Щербакова ЛВ, Воевода МИ. Валидизация финской шкалы риска «FINDRISC» на европеоидной популяции Сибири. Сахарный диабет [Internet]. 2016;19(2):113–118. doi: 10.14341/DM200418-10

The authors declare that there are no conflicts of interest present.